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ABSTRACT 
 
 The Borrelia burgdorferi sensu lato (s.l.) complex contains species 
carried by hard-shell ticks (Ixodes spp.) causing Lyme disease and related 
non-pathogenic species. Relapsing fever Borrelia includes both tick-borne 
(soft-shell, Ornithodoros spp.) and louse-borne species knowns to cause 
relapsing fever. A subgroup includes relapsing fever spirochetes carried by 
hard-shell ticks, including B. miyamotoi, an emerging pathogen. Despite 
bordering high-risk counties in Minnesota, little attention has been given to 
Lyme disease, B. burgdorferi, I. scapularis, or reservoirs in eastern North 
Dakota. Reports of B. burgdorferi and I. scapularis in North Dakota, however, 
prompted a more detailed examination. Through trapping Peromyscus and 
Myodes, five B. burgdorferi populations were obtained. We confirmed the 
presence of established, unique (nonclonal), and infectious B. burgdorferi 
populations in eastern North Dakota. Species of the B. burgdorferi s.l. 
complex possess two highly conserved hypothetical genes, bb0399 and 
bbb28, containing one of the most common protein motifs, ankyrin-repeat 
domains. The goal was to identify the function(s) of bb0399 and bbb28. Our 
hypothesis was BB0399 is an essential DNA binding protein and BBB28 is 
regulated by the Borrelia oxidative stress response regulator, BosR in 
response to unknown stimuli. Exposing B. burgdorferi to tert-butyl 
hydroperoxide increased transcription of bbb28 but not bb0399. Several 
xviixvii 
xvii 
attempts to express recombinant BB0399 and BBB28 failed and the 
functionsof bb0399 and bbb28 remain unknown. B. miyamotoi is an 
emerging pathogen vectored by the same Ixodes spp. carrying and 
transmitting B. burgdorferi. B. miyamotoi binds human factor H in vitro. 
C57BL/6J Rag1-/- mice infected with a Japanese strain of B. miyamotoi, 
FR64b, developed a chronic infection, while both 2-4 and 6-8 week-old wild-
type C3H/HeN groups cleared B. miyamotoi. B. miyamotoi FR64b, normally 
vectored by I. persulcatus, was acquired by North American I. scapularis and 
maintained B. miyamotoi throughout the molting process from larvae to 
nymph, suggesting unlike other relapsing fever Borrelia, B. miyamotoi is not 
vector specific. 
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CHAPTER 1 
 
AN INTRODUCTION TO BORRELIA BURGDORFERI  
AND BORRELIA MIYAMOTOI 
 
 An array of viral, bacterial, and parasitic pathogens cause tick-borne 
diseases. Tick-borne pathogens are transmitted through the bite of an 
infected hard- or soft-shell tick belonging to four genera (Ixodes, 
Dermacentor, Amblyomma, and Ornithodoros) (1–3). This group of diseases 
include Lyme disease (Borrelia burgdorferi sensu lato), tick-borne relapsing 
fever (Borrelia), anaplasmosis (Anaplasma phagocytophilum), rickettsiosis 
(Rickettsia), babesiosis (Babesia), Powassan virus (Flavivirus), tick-borne 
encephalitis virus (Flavivirus), Colorado tick fever (Coltivirus), and Heartland 
virus (Phlebovirus) to name a few.  
Borrelia 
 
 Species of the B. burgdorferi sensu lato (s.l.) complex are primarily 
carried by Ixodes spp. (Ixodidae; hard shell). The s.l.  complex includes nine 
Borrelia spp. causing Lyme disease and approximately 11 non-pathogenic but 
genetically similar Borrelia spp. (Table 1.1) (4–16). Borrelia spp. that cause 
tick-borne relapsing fever (TBRF) are primarily carried by Ornithodoros spp. 
(Argasidae; soft shell) (Table 1.1). Relapsing fever Borrelia are genetically 
distinct from B. burgdorferi s.l. species but are genetically similar to each 
other (Fig. 1.1). 
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Table 1. 1.  Borrelia spp. confirmed to cause human disease and associated 
vectors. NA – North America, Eu – Europe, As – Asia, Af – Africa. 
Disease Causative agent(s) Vector(s) 
Lyme disease B. burgdorferi sensu 
stricto (s.s.) (NA, Eu) 
B. mayonii (NA) 
B. bissettii (NA, Eu) 
B. lusitaniae (Eu) 
B. valaisiana (Eu) 
B. afzelii (Eu, As) 
B. garinii (Eu, As) 
B. spielmanii (Eu, As) 
B. bavariensis (Eu, As; 
formerly B. garinii 
OspA serotype 4) 
I. scapularis (NA) 
I. pacificus (NA) 
I. ricinus (Eu, As) 
I. persulcatus (Eu, As) 
Tick-borne relapsing 
fever 
B. hermsii (NA) 
B. turicatae (NA) 
B. parkeri (NA) 
B. duttonii (Af) 
B. crocidurae (Af) 
B. hispanica (Eu, Af) 
B. latyshevi (As) 
B. persica (As, Af) 
O. hermsi (NA) 
O. turicata (NA) 
O. parkeri (NA) 
O. moubata (Af) 
O. erraticus; O. sonrai 
(Af) 
O. erraticus (Eu, Af) 
O. tartakovski (As) 
O. tholozani (As, Af) 
Hard tick-borne 
relapsing fever 
B. miyamotoi (NA, Eu, 
As) 
I. scapularis 
I. pacificus 
I. ricinus 
I. persulcatus 
Louse-borne relapsing 
fever 
B. recurrentis (Af) P. humanus humanus 
(Af) 
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Figure 1. 1.  Maximum likelihood phylogenetic analysis of Borrelia flagellin. 
B. burgdorferi s.l. species form a distinct, monophyletic clade; 
relapsing fever Borrelia do not form a monophyletic clade, 
however, they are separate from Lyme Borrelia species. 
Values at nodes represent bootstrap values from 1000 
replicates. Species of the B. burgdorferi s.l. complex (Lyme) 
are shown in blue, relapsing fever Borrelia vectored or carried 
by soft-shell ticks (Ornithodoros, Argas) are red, relapsing 
fever Borrelia vectored by lice (Pediculus) is pink, relapsing 
fever Borrelia vectored or carried by hard-shell ticks (Ixodes, 
Amblyomma, Hyalomma, Rhipichephalus) are purple, and an 
outgroup (Leptospira) is orange. 
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 The general classification for Borrelia currently holds as several Lyme 
disease Borrelia are associated with hard-shell ticks and relapsing fever 
Borrelia are associated with soft-shell ticks. However, five exceptions have 
been documented. B. recurrentis is a louse-borne relapsing fever spirochete 
presently endemic predominantly to sub-Saharan Africa. B. theileri is the 
causative agent of bovine borreliosis and is transmitted by Rhipicephalus 
microplus, a hard-shell tick that parasitizes livestock (17). B. lonestari and B. 
turcica are genetically similar to relapsing fever borreliae and carried by the 
hard-shell ticks Amblyomma americanum and Hyalomma aegyptium, 
respectively (18, 19). The status of B. lonestari and B. turcica as an animal 
or human pathogens is unknown. Finally, B. miyamotoi is a relapsing fever 
spirochete vectored by the same Ixodes spp. transmitting species of the B. 
burgdorferi s.l. complex (20, 21). 
The Unusual Nature of B. burgdorferi S.L. Genetics  
 
 All known Borrelia spp. have unusual genomes compared to traditional 
bacterial genomes, which consist of a circular chromosome. Species of the B. 
burgdorferi s.l. complex have a highly fragmented genome comprised of a 
linear chromosome (ca. 910 kilobases [kb]) and an array of linear and 
circular plasmids (size from ca. 5 to 54 kb) (22). Twelve linear and nine 
circular plasmids have been characterized from the B. burgdorferi s.s. B31 
type strain, though the number and arrangement of plasmids vary by B. 
burgdorferi s.l. strain (23, 24).  
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 The chromosome mainly consists of essential genes (e.g. metabolism, 
motility, replication) and appears to be stable (22, 25). Some essential genes 
are found on plasmids thereby making those plasmids essential. The 
presence of essential plasmids is in stark contrast to traditional bacterial 
genomes where plasmids are usually unessential or extra-chromosomal 
genetic elements. However, it should be noted the definition of “essential 
plasmid” requires consideration of the environment and B. burgdorferi exists 
in several environment types: in vivo in ticks (fed and unfed), in vivo in 
numerous reservoirs and hosts, and in vitro in laboratory cultures. A plasmid 
required for survival in a mouse may not be required for survival in a tick. 
Prolonged in vitro passage results in strains losing plasmids (likely due to a 
lack of selective pressure), which are required for establishing or maintaining 
an infection in mice and/or ticks resulting in non-infectious isolates (26, 27). 
The loss of plasmids, however, is not universal as some isolates do retain 
plasmids and, thus, infectivity (28). 
 The genome, in terms of open reading frames (ORFs), is significantly 
reduced compared to free-living bacteria but is on par with genome sizes of 
other obligate parasitic bacteria such as Rickettsia and Chlamydia. B. 
burgdorferi B31 currently has 1427 putative or known ORFs and 136 
pseudogenes (22, 29). Of these 1427 ORFs, 588 (41.2%) are predicted 
“hypothetical proteins,” or proteins meeting all the requirements to be 
functional but lacking empirical data to demonstrate functionality. Very few 
hypothetical proteins reside on the chromosome (26.4%) as many of these 
are essential genes that have been assigned a function either through 
7 
identification of conserved domains and/or empirically. By comparison, 50% 
of ORFs on 16 of the 21 plasmids found in B. burgdorferi B31 are 
hypothetical proteins. Function and functionality of many of these will require 
experimental data as only approximately 7.9% of predicted ORFs on B. 
burgdorferi’s plasmids share homology to proteins from any genera outside 
of Borrelia (30).  
Relapsing Fever Borrelia Genetics is also Unusual 
 
 Relapsing fever species also share similar genetic traits though much 
less is known about relapsing fever Borrelia as sequence data for most 
species is still incomplete. As a result, much of what we know about 
relapsing fever Borrelia comes from work with B. hermsii. Like species of the 
B. burgdorferi s.l. complex, relapsing fever Borrelia have a linear 
chromosome (ca. 923 kb) and several circular plasmids homologous to the B. 
burgdorferi s.l. cp32 family (31, 32). Unlike B. burgdorferi s.l. spp., relapsing 
fever Borrelia also have a linear megaplasmid (ca. 183 kb). B. hermsii HS1 
(type strain) also has two circular plasmids (ca. 6.5 and 28.8 kb) and seven 
linear plasmids (size from ca. 27 to 58 kb) (32). 
 Of the 1272 ORFs, 36.6% are predicted hypothetical proteins. 
However, the vast majority of these hypothetical proteins are found on the 
plasmids (ranges from linear plasmid B58 with 43.8% ORFs predicted as 
hypothetical proteins to the megaplasmid with 87.9% hypothetical protein 
ORFs). As with B. burgdorferi B31, the chromosome of B. hermsii HS1 has 
the fewest hypothetical proteins (19.9%). Given the number of hypothetical 
proteins predicted on B. hermsii plasmids, we presume a similarly small 
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percentage of predicted ORFs in B. hermsii lack homology to proteins from 
genera outside Borrelia and will require empirical testing to determine the 
function and functionality of many of these proteins. 
Vectors and Associated Borrelia spp.  
 
 There are distinct morphological differences between Ixodes and 
Ornithodoros ticks. Ixodes possess a hard plate on the back (dorsal scutum). 
Ornithodoros, on the other hand, have leathery but soft skin. Ixodes have 
mouthparts visible from dorsal and ventral perspectives, while Ornithodoros 
mouthparts are only visible when observing the ventral side. In addition to 
the gross anatomical differences, there are also behavioral differences 
between Ixodes and Ornithodoros that may contribute to differences 
observed between B. burgdorferi s.l. spp. and relapsing fever Borrelia. 
Life Cycle of Ixodes and Enzootic Cycle of B. burgdorferi s.l.  
 
 Ixodes have a two-year, four-stage life cycle (Fig. 1.2). During year 1, 
eggs are laid in spring and hatch to larvae in summer. Larvae will feed on 
their first host, typically a small to medium mammal, rodent, or bird, some of 
which are competent reservoirs for B. burgdorferi s.l. spp. Indeed, the larval 
bloodmeal is a crucial point in the enzootic cycle of B. burgdorferi s.l., which 
is not transovarially maintained in ticks. That is, an infected adult cannot 
pass B. burgdorferi s.l. to the eggs. Ixodes can only acquire B. burgdorferi 
s.l. by feeding on an infected reservoir. As a result, Lyme disease is not 
considered be obtained through the bite of a larval Ixodes. After feeding, 
replete Ixodes will detach and find refuge in a suitable habitat for the fall and 
winter months. During year 2, larvae will molt to nymphs, emerge in the 
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Figure 1. 2.  Life cycle of Ixodes spp. and enzootic cycle of B. burgdorferi 
s.l. Larvae (six legs) feed on small- to medium-sized animals, 
providing the first opportunity for Ixodes to acquire B. 
burgdorferi s.l. After feeding, larvae molt into nymphs (eight 
legs) and feed on medium- to large-sized animals. A final 
bloodmeal is consumed by adult females and pairs mate on a 
medium- to large-sized animals. Females will drop from the 
host to lay eggs. 
 
 
spring, and seek its next bloodmeal. Nymphs will usually feed on small to 
medium mammals, rodents, and birds. After detaching, nymphs will molt and 
emerge as adults during the fall of year 2. Adults will find a medium to large 
mammal, in particular, Odocoileus virginianus (white-tailed deer), a common 
host for adults. Females, but not males, will take a bloodmeal and both will 
mate. Males die shortly after mating, while females will drop from the host, 
find suitable habitat, and lay eggs.  
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 Each life stage feeds once but Ixodes are considered generalist 
feeders. Even though there are preferences for hosts (e.g. larvae tend to 
feed on Peromyscus or white-footed mice more often than other hosts), as a 
whole, Ixodes spp. feed on a variety of animals (33–45). Humans and 
domestic animals can become hosts for all stages of Ixodes but are 
considered dead-end hosts for B. burgdorferi s.l. as neither can sustain an 
enzootic cycle. Species of the B. burgdorferi s.l. complex are not maintained 
transovarially, a subject of debate for years. In retrospect, early reports of B. 
burgdorferi being transovarially transmitted (46) were likely due to the 
presence of B. miyamotoi, a relapsing fever spirochete transmitted by Ixodes 
spp. discovered in 1995 (20). To become infected with B. burgdorferi s.l., 
ticks must feed on an infected animal and any stage can acquire B. 
burgdorferi s.l. Larvae cannot transmit Lyme disease, thus the largest threat 
for humans and domestic animals to acquire B. burgdorferi s.l. from ticks 
come from unfed nymphs and adult females. Adult males can be infected, 
however, since adult males do not typically partake in a bloodmeal, they 
rarely transmit B. burgdorferi s.l. (47). 
 It is important to note the general perception of Ixodes, including host 
preference by different life stages and even active periods, is based on the 
most studied and largest endemic region for Lyme disease in North America, 
Northeastern US. However, as we understand more about Lyme disease (i.e. 
Ixodes, B. burgdorferi s.l., reservoirs, and hosts) in the upper Midwest, 
southern US, California, Canada, Europe, and Asia, it is clear we need to view 
Lyme disease as a regional disease, especially in terms of the maintenance of 
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B. burgdorferi s.l., the chance to acquire Lyme disease, and public health 
strategies for controlling Lyme disease.  
 P. leucopus (white-footed mouse) is a primary reservoir for B. 
burgdorferi s.s. in the northeastern US and host for larval I. scapularis (48, 
49, 49–52). In the upper Midwest, P. leucopus and P. maniculatus (deer 
mouse) are both major reservoirs and hosts. However, in California, the list 
of Ixodes hosts is long and several species are competent reservoirs for B. 
burgdorferi s.l., including western grey squirrels (Sciurus griseus), California 
kangaroo rats (Dipodomys californicus), and dusky-footed wood rats 
(Neotoma fuscipes) (53–55). These species, not the Peromyscus spp. 
present, represent the primary reservoirs for B. burgdorferi s.l. in California. 
The primary hosts for larval and nymphal I. pacificus, however, are lizards, 
particularly the western fence lizard (Sceloporus occidentalis) and the 
southern alligator lizard (Elgaria multicarinata) (53). Both lizards are 
refractory hosts for B. burgdorferi s.l. Likewise, in Europe and Asia, there 
does not appear to be a single, predominant reservoir as a diverse population 
of rodents, small and medium mammals, and birds serve as adequate B. 
burgdorferi s.l. reservoirs and Ixodes hosts (56).  
Life Cycle of Ornithodoros and Enzootic Cycle of Tick-Borne  
Relapsing Fever (TBRF) Borrelia  
 
 Unlike Ixodes, Ornithodoros have a multi-year life cycle that is not 
dictated by climate (Fig. 1.3). Eggs hatch into larvae, which feed on their 
first host. Ornithodoros spp. are considered specialized feeders. Collectively, 
Ornithodoros parasitize myriad mammals, rodents, and birds. Each species, 
however, has preferred hosts and each individual Ornithodoros population 
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Figure 1. 3.  Life cycle of Ornithodoros spp. With the exception of 
Ornithodoros eggs, each stage generally feeds upon the same 
host species and is capable of acquiring and transmitting 
relapsing fever Borrelia. 
 
 
will be limited primarily to one host. After feeding, larvae detach and molt to 
nymphs. Ornithodoros spp. have multiple nymphal stages. Each nymphal 
stage will feed, detach, and molt to a new nymphal stage. After 
approximately seven nymphal stages, Ornithodoros will molt to an adult. In 
stark contrast to Ixodes, adult Ornithodoros can feed, without molting, 
several times. Eventually, adults will mate and lay eggs.  
 Tick-borne relapsing fever (TBRF) Borrelia carried by Ornithodoros are 
transovarially maintained. Thus, a tick can acquire Borrelia during any 
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feeding (if the host is infected) or from an infected adult female. As with 
Ixodes, humans and domestic animals can become incidental hosts for 
Ornithodoros and dead-end hosts for relapsing fever Borrelia.  
Habitats and Behavior of Ixodes and Ornithodoros  
 
 The geographic distribution of Ixodes spp. is governed by the 
distribution of hosts and limited by temperature and humidity, with ticks 
preferring environments with warm, humid summers and mild winters (57). 
While off-host I. scapularis are highly susceptible to desiccation and low 
temperature in laboratory experiments, established populations have been 
found in regions that experience frigid and dry winters (38, 58–60). This 
suggests that microclimates are invaluable for I. scapularis survival. 
Deciduous and mixed forests provide leaf litter that maintains high relative 
humidity and are regarded as the classic microhabitat for ticks. However, 
several temperate biomes, including coniferous forests, grasslands, and 
pastures also maintain microclimates that sustain Ixodes spp. (61–64) some 
urban, peri-urban, and recreational environments support or are capable of 
supporting Ixodes spp. and host populations (65–67).  
 Ixodes find hosts by questing. Ticks will crawl up vegetation, extend 
their front legs, and wait for something, hopefully, a tasty bloodmeal and not 
a researcher’s collection cloth, to brush against the vegetation. The tick will 
attach and begin feeding. Desiccation is not a concern during feeding as ticks 
absorb water from the bloodmeal. If a suitable bloodmeal is not obtained and 
desiccation is a concern, Ixodes will crawl back to their humid habitat. Ixodes 
are long-term, slow feeders, remaining attached to a host for approximately 
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three to five days. Long attachment times, as well as the open environments 
Ixodes inhabit, facilitates dispersal of a population, especially if Ixodes 
attaches to a migrating mammal or bird.  
 Ornithodoros, in comparison, are found in more contained 
environments such as animal dens, burrows, and nests. As a result, 
Ornithodoros do not need to “hunt” for a bloodmeal and desiccation is less of 
a concern. Ornithodoros are short-term, quick feeders, able to attach, feed, 
and detach from a host in minutes to hours. Not surprisingly, dispersal of 
Ornithodoros populations is quite limited.  
Borrelia spp. Suitably Adapted to the Differences in Vector  
 
 B. burgdorferi s.l. are found in the tick midgut. When an infected 
Ixodes feeds, Borrelia must sense a bloodmeal is occurring and begin 
migrating from the midgut to the salivary glands and into the feeding pit 
while shifting gene expression from tick-phase genes to mammalian-phase 
genes. This process can take time for the slow-replicating microbe and works 
quite well with Ixodes’ long attachment time.  
 A feeding nymph is the last chance B. burgdorferi s.l. has to ensure 
survival of its genetic material since B. burgdorferi s.l. is not transovarially 
maintained, Ixodes feed once per life stage, adult males do not feed, and 
adult female Ixodes typically feed on deer, which are not competent 
reservoirs for B. burgdorferi s.l. (68). TBRF Borrelia, on the other hand, are 
found in the salivary glands of infected Ornithodoros, which allows for rapid 
transmission from tick to host (69). With nymph and adult Ornithodoros 
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capable of multiple feedings per life stage, TBRF Borrelia have ample 
opportunities for transmission to and from a host.  
 An important and intriguing, but not yet understood difference 
between B. burgdorferi s.l. and relapsing fever Borrelia involves vector 
specificity, exclusivity, and complementarity. Vector specificity occurs when 
serologically distinct bacterial strains have closely related vectors; vector 
exclusivity occurs when one vector species carries one bacterial strain; and 
vector complementarity occurs when one vector species carries multiple 
bacterial strains (70, 71). An unspoken assumption is that species of the B. 
burgdorferi s.l. complex are not vector specific or exclusive. That is, any 
species of the B. burgdorferi s.l. complex is assumed to be able to establish 
an infection in any Ixodes spp. While no experiments have shown exclusivity, 
numerous surveys have cataloged the species of the B. burgdorferi s.l. 
complex found in species of Ixodes. From these surveys and basic knowledge 
of evolution, it appears some B. burgdorferi s.l. species are exclusive. For 
example, B. bavariensis NT29, an Asian strain, is only found in I. persulcatus, 
an Asian species, while European B. bavariensis strains are only found in the 
European I. ricinus (72–74). Whether B. bavariensis demonstrates exclusivity 
or simple geographic isolation remains unknown. An experiment attempting 
to infect I. ricinus with an Asian strain of B. bavariensis is required. Other 
species of the B. burgdorferi s.l. complex appear to be highly promiscuous. 
B. burgdorferi s.s. has been found in I. scapularis, I. pacificus, I. ricinus, and 
I. persulcatus. There may be strain restrictions, such that B. burgdorferi s.s. 
B31 may not infect any species of Ixodes except I. scapularis. Still, the 
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degree of specificity or exclusivity that may be present with B. burgdorferi 
s.l. species pales in comparison to the exclusivity observed with relapsing 
fever Borrelia. To date, all relapsing fever Borrelia identified are exclusive to 
their respective vector, despite some significant overlap in geographic 
distribution for some Ornithodoros spp. (75). That is, B. hermsii cannot 
establish an infection in O. turicata; B. hermsii can only infect O. hermsi. The 
mechanism by which this exclusivity occurs is still not understood. 
Tick-Borne Spirochete Diseases  
 
Lyme Disease  
 
 Diseases caused by Borrelia burgdorferi s.l., especially Lyme disease, 
are relatively new diseases to be described. The first recorded account of 
erythema migrans (EM), an inconsistent but distinguishing symptom of Lyme 
disease, was made in Europe in 1909 by Dr. Arvid Afzelius (76). While 
unconfirmed at the time, Dr. Afzelius suspected a tick bite (I. ricinus) was 
involved in the development of EM. Lyme disease went unrecognized in the 
US until an outbreak of juvenile rheumatoid arthritis occurred in Connecticut 
in 1977 (77). By 1982, Dr. Willy Burgdorfer had isolated spirochetes from I. 
scapularis (I. dammini) and shown antibodies to B. burgdorferi reacted 
strongly with sera from Lyme disease patients (4).  
 Lyme disease is the top tick-borne disease reported to the Centers for 
Disease Control and Prevention (CDC), with 38,069 confirmed and probable 
cases reported in 2015. However, in 2012, the CDC released estimates 
indicating the number of people infected with Lyme disease is underreported 
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by about 10% and the actual number of cases in the US is closer to 300,000 
(78). 
 Symptoms of Lyme disease in humans vary by species and shows a 
distinct geographical pattern, though some symptoms are universal 
(Table 1.2) (79, 80). In North America, where the primary etiological agent is 
B. burgdorferi s.s., early stage Lyme disease (3-30 days post-infection) is 
characterized by influenza-like symptoms (e.g. mild fever, malaise, 
myalgia/arthralgia) and an associated, though not guaranteed, bullseye rash 
(erythema migrans). Arthritis is a key symptom of late stage Lyme disease 
(after 30 days post-infection). Lyme neuroborreliosis and carditis are also 
late stage Lyme symptoms in the US, though the prevalence is much lower 
compared to arthritis. In Europe, however, late-stage symptoms are more 
diverse because there are more pathogenic Borrelia spp. present. B. 
burgdorferi s.s. is found in Europe but is not a predominant strain. Thus, 
Lyme arthritis does occur but at significantly lower rates compared to North 
America. Acrodermatitis chronica atrophicans is a common late stage 
symptom caused by B. afzelii. Neurological symptoms (Lyme 
neuroborreliosis) characterized by numbness, Bell’s palsy, neck stiffness, 
declining memory, and sleep disorders are also common late-stage 
symptoms associated with B. bavariensis infection. Infection with B. 
burgdorferi s.l. is not self-resolving and does require treatment, usually a 
course of ceftriaxone or doxycycline (81).
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Table 1. 2.  Clinical symptoms of human Borrelia diseases. 
Disease Clinical symptom(s) 
Lyme disease Symptom onset after exposure: early stage generally 3-30 days 
–Influenza-like (e.g. mild fever, malaise, myalgia/arthralgia; B. 
burgdorferi s.s.) 
–Erythema migrans (B. burgdorferi s.s., B. afzelii) 
–Symptom onset after exposure: late stage generally > 30 days 
–Arthritis 
–Acrodermatitis chronica atrophicans (B. afzelii) 
–Neurological (Lyme neuroborreliosis, e.g. numbness, Bell’s 
palsy, stiffness of neck, declining memory, sleep disorders; B. 
burgdorferi s.s., B. bavariensis) 
 
Tick-borne 
relapsing fever 
Symptom onset: ca. 7 days 
–Influenza-like 
–Recurring high fever 
–Headache 
–Myalgia 
–Arthritis 
 
Approximately 3-10 febrile episodes (relapses) occur; mortality 
rates are variable but generally less than 5% 
Hard tick-
borne 
relapsing 
fever/Borrelia 
miyamotoi 
disease 
Symptom onset after exposure: ca. 15 days (82) 
–Influenza-like 
–Most common: 
–Fever  
–Malaise 
–Headache 
–Chills 
–Arthritis/arthralgia 
–Meningoencephalitis (immunocompromised patients) 
 
Rare (less than 10% of patients): 
–Rash/Erythema migrans 
–Gastrointestinal (e.g. vomiting, nausea, diarrhea) 
–Cardiac/respiratory (shortness of breath) 
–Neurological (e.g. dizziness, confusion) 
–Stiffness of neck 
Louse-borne 
relapsing fever 
Symptom onset after exposure: ca. 4-8 days 
–Recurring high fever 
–Malaise 
–Headache 
–Chills 
–Meningism 
–Myalgia 
–Nausea 
–Vomiting 
 
Approximately 3-5 relapses occur; mortality rate varies greatly 
(30-70% without treatment during outbreaks) 
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Tick-Borne Relapsing Fever 
 
 Unlike Lyme disease, TBRF is not nationally reportable. TBRF is, 
however, reportable in 11 endemic states (California, Washington, Colorado, 
Idaho, Nevada, Oregon, Arizona, Texas, New Mexico, Montana, Utah, 
Wyoming) and one bordering state (North Dakota, note no TBRF cases have 
been reported in North Dakota). Approximately 70% of TBRF cases are 
reported in California, Washington, and Colorado. Data collected from these 
12 states between 1990 and 2011 indicate 504 cases of TBRF have been 
reported (83).  
 There is less diversity in the symptoms of TBRF in humans. Influenza-
like symptoms appear approximately seven days post-infection (Table 1.2). 
The defining characteristic of TBRF is recurring spirochetemia events leading 
to febrile episodes. TBRF can be fatal (mortality rate is generally less than 
5%) but is usually self-resolving after approximately three to ten recurring 
febrile episodes. Louse-borne relapsing fever (B. recurrentis) has similar 
symptoms though approximately three to five febrile episodes occur and 
mortality can be much higher (30-70% without treatment during outbreaks).  
Hard Tick-Borne Relapsing Fever or  
Borrelia miyamotoi Disease 
 
 Hard tick-borne relapsing fever (HTBRF) or Borrelia miyamotoi disease 
(BMD) is an emerging disease first described in 2011 (82). Numerous cases 
have been documented for Lyme disease and TBRF allowing for a defined set 
of typical symptoms. Much of the data currently available for B. miyamotoi 
infections come from retrospective serological analyses of banked patient 
samples, which provide valuable epidemiological information but can lack the 
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detailed patient history or clinical aspects required to sufficiently define a 
disease. Two large studies in Russia (82) and the US (84) suggest HTBRF is a 
disease similar to TBRF.  
 The Russian patients described by Platonov et al (82) reported tick 
bites, developed moderate or severe disease, and were hospitalized as a 
precautionary measure against more severe tick-borne diseases, particularly 
viral tick-bone encephalitis. Forty-six patients were classified as having a 
confirmed B. miyamotoi infection with no detected current B. burgdorferi s.l. 
coinfection by PCR though all patient sera reacted with whole cell lysates of 
B. burgdorferi s.s., B. afzelii, and B. garinii. The most common symptoms 
were fever, headache, and malaise or fatigue (Table 1.3). Five patients 
reported recurrent fever with an average duration of 3.4 days, and 9 days 
between relapses, a similar timeline for TBRF. All patients were successfully 
treated with ceftriaxone or doxycycline.
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Table 1. 3. Comparison of B. miyamotoi symptoms reported from US (84) and 
Russian (82) patients 
Symptom US (n = 51) Russia (n = 46) 
Fever, chills 96% 96%, 35% a 
Headache 96% b 89% 
Myalgia 84% 59% 
Arthralgia 76% 28% 
Malaise/fatigue 82% 98% 
Rash/EM c 8% 9% 
Gastrointestinal d 6% 30% (nausea) 
7% (vomiting) 
Respiratory e 6% na f 
Neurological (dizziness, 
confusion, vertigo) 
8% na 
Stiff neck na 2% 
a Fever and chills were reported in separate categories 
b Authors noted in most patients the headaches were severe 
c US patients were described as having a rash. Russian patients were noted for 
having a single erythema migrans 
d For US patients, GI symptoms included nausea, abdominal pain, diarrhea, 
anorexia. For Russian patients, GI symptoms included nausea and vomiting 
e Labored breathing or shortness of breath 
f Not reported 
 
 
 In the US, 97 of 11.515 patient samples submitted by clinical 
laboratories for tick-borne disease analysis were PCR-positive for B. 
miyamotoi (84). Patients with known or suspected B. burgdorferi s.s. 
coinfection or a history of Lyme disease were omitted from further analysis. 
Fever, headache, and malaise were commonly reported among US patients 
with two patients reporting recurrent fever (Table 1.2). The duration of 
febrile episodes and the time between relapses were not reported. 
Spirochetemia was noted in US patients but either not reported or 
documented in Russian patients. Strikingly, a rash or single erythema 
migrans of unknown origin, a symptom associated with B. burgdorferi s.l. 
infections, was reported in 8 and 9% of US and Russian patients, 
respectively.  
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 In addition, some symptoms were different between US and Russia 
patients, which suggest clinical manifestations vary by B. miyamotoi strain, 
similar to that seen with B. burgdorferi s.l. strains (Table 1.2) (80). 
Arthralgia was more common in US (76%) compared to Russian patients 
(28%), and leukopenia, thrombocytopenia, and elevated liver enzymes were 
found in some US patients but none of the Russian patients. These 
differences may be explained by genetic differences between American and 
Asian type B. miyamotoi. Genetic analyses of B. miyamotoi isolates reveal 
heterogeneity between, and a high degree of homology among, strains from 
the US (American types; I. scapularis, I. pacificus), Europe (European type; 
I. ricinus), and Asia (Asian type; I. persulcatus) (85, 86). 
 Detailed case reports are currently available for nine patients in the 
US, Europe, and Japan. For immunocompetent patients, symptoms were 
similar to those observed in the aforementioned studies (e.g. fever, 
headache, malaise) (87–91). One US patient did not seek treatment, 
providing additional evidence that B. miyamotoi can result in recurrent fever 
and be self-resolving, similar to other relapsing fever infections (92, 93). This 
patient experienced two episodes of fever separated by three weeks, 
significantly longer than in other B. miyamotoi or relapsing fever patients, 
with each episode lasting 4-5 days, on par with B. miyamotoi or relapsing 
fever patients.  
 The pathology of B. miyamotoi infection is dramatically different in 
immunocompromised patients, specifically, those treated for non-Hodgkin’s 
lymphoma (NHL) treated with rituximab. Two patients treated with rituximab 
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for NHL, one from the US (94) and one from the Netherlands (95), with 
reported recent tick bites developed meningoencephalitis. Motile spirochetes 
were detected in cerebral spinal fluid in both cases. Interestingly, glpQ 
(glyphosphodiesterase; among Borrelia, glpQ is unique to relapsing fever 
Borrelia) was amplified and sequenced from both patient’s samples yet no 
anti-GlpQ antibodies were detected in the blood or cerebral spinal fluid of the 
European patient. IgM against B. burgdorferi was negative for both patients. 
Neither patient reported any of the commonly associated symptoms of a B. 
miyamotoi infection (e.g. fever, headache, myalgia, malaise). Instead, both 
patients exhibited neurological symptoms (cognitive processing defects, 
disturbed gait). A third patient from Germany, also with treated with 
rituximab for NHL developed Lyme neuroborreliosis-like symptoms 
(dizziness, vomiting, and headache) (96).  
General Immune Responses and  
How Borrelia Deal with Them 
 
 To establish long-term infection in rodents and mammals (late or 
disseminated phase of Lyme disease in humans), B. burgdorferi s.l. migrates 
to various sites, such as joints, skin, heart, and bladder (97–105). These 
sites offer much protection from cells of the immune system, however, 
Borrelia has not unlocked the mysteries of teleportation. As a result, B. 
burgdorferi s.l. must migrate to these sites from the inoculation site (tick 
bite) and will encounter immune cells producing complement and a humoral 
immune response. Ixodes saliva contains adaptive and innate 
immunomodulatory and anti-complement proteins that offer some protection 
for B. burgdorferi s.l. (106–113). B. burgdorferi s.l. possess a handful of anti-
24 
complement proteins with the best understood being factor H binding 
proteins (114–117). The ability to bind and neutralize complement through 
binding factor H is vital for B. burgdorferi s.l. to establish infection (114). 
 Relapsing fever Borrelia migrate from the inoculation site to the blood 
where they remain until cleared by the immune system. Ornithodoros 
salivary gland extracts also possess proteins that inhibit the host immune 
response (118–121). Despite possessing factor H binding proteins, 
complement is not an effective method for relapsing fever Borrelia to 
establish infection, meaning complement is not the primary mechanism to 
clear relapsing fever Borrelia (122, 123). Instead, the primary mechanism for 
clearance is an humoral response. 
 The humoral response is important for controlling and preventing both 
B. burgdorferi s.l. and relapsing fever Borrelia infections (124–131). Indeed, 
these responses form the basis of an intense research effort for effective 
Lyme vaccines. Fortunately for Borrelia, they are quite adept at evading the 
host humoral response primarily through variation of surface-exposed 
proteins. Lyme disease Borrelia possess outer surface proteins (Osps) and 
variable membrane protein-like (Vls) proteins, while relapsing fever Borrelia 
possess variable membrane proteins (Vmps; include variable large and 
variable small proteins) (132–136).  
Osps and VlsE of Lyme Borrelia 
 
 The outer surface proteins (Osps), particularly OspC, are one of the 
most studied groups of Borrelia proteins (117, 137, 138). ErpA (OspE) and 
OspF are factor H-binding proteins. OspA, a protein predominantly involved 
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in uptake and survival in tick, is immunogenic and able to block antibody 
binding to another surface-exposed protein, P66 (139, 140). OspC has 
diverse roles, many of which are essential for transmission from Ixodes and 
establishing infection in mammals (141–148). These studies were key in 
demonstrating that ospC is upregulated during the early stages of infection, 
downregulated after infection has been established, and deleting or 
overexpressing ospC results in spirochetes that are quickly cleared from a 
host. 
 A handful of immune evasion functions have been identified for OspC. 
OspC protects Borrelia by binding Salp15, an Ixodes salivary protein. OspC 
also prevents phagocytosis by macrophages (148). In addition, several OspC 
types have been identified and correlated with a strains ability to establish 
infection in hosts and reservoirs (98, 99, 149–152). However, as each Osp is 
present as a single-copy locus, genetic variation is seen at the population 
level. That is, outside of random mutation or horizontal gene transfer events, 
a single spirochete cannot produce different OspC types in situ.  
 In contrast, the Vls (Vmp-like sequences) system can change the 
expressed surface antigen in situ (Fig. 1.4). Antigenic recombination of VlsE 
is important in maintaining infection in mammals and helps Lyme Borrelia 
evade the humoral immune response (153–166). The Vls system is 
composed of approximately 16 vls cassettes (the exact number varies by 
strain) and one expression locus, vlsE. All of the identified vls cassettes are 
located on the same plasmid (lp28-1) in close proximity to but in the 
opposite direction of vlsE. Expression at vlsE occurs through the random 
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Figure 1. 4.  Antigenic variation of Lyme borreliae VlsE and relapsing fever 
borreliae Vmp systems. (A) VlsE. The expression locus (vlsE) 
is located near the telomere of linear plasmid (lp) 28-1 (blue 
or green arrow, promoter is indicated by a black arrow).  
Silent vls cassettes are located upstream and in the opposite 
orientation of vlsE. Antigenic variation occurs through the 
random and sequential insertion of silent cassette fragments 
(labeled 1, 2, and 3). (B) vlp (pink arrows) and vsp (purple 
arrows) cassettes are located throughout the genome on 
lp28-1, 28-2, 28-3, 28-4, and 32-1. The expression locus 
(blue or green arrow, promoter is indicated by a black arrow) 
is found on lp28-1 near the telomere (open oval). Changing 
the expressed Vmp cassette is achieved through deletion of 
the current cassette (blue arrow) followed by insertion of a 
copy of a new cassette (green arrow via recombination 
events) resulting in a change in the expressed Vmp on the 
surface of the bacterium (denoted by blue or green triangles, 
respectively). Grey arrows indicate non-Vmp ORFs; tan 
arrows indicate downstream homology sequences (DHS, 
sequences found throughout the genome and required for 
mapping recombination events at the Vmp expression locus). 
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recombination of segments of multiple vls cassettes rather than 
recombination of an entire, single vls cassette. Thus, recombination events 
result in thousands of unique VlsE variants, all approximately 36-kD. 
Vmps of Relapsing Fever Borrelia  
 
 Vmps, a system similar to Vls, are one of the best characterized 
immune evasion mechanisms (132, 167–170). B. hermsii has approximately 
60 unique and promoterless vmp cassettes (i.e. silent cassettes) scattered 
throughout its genome and one promoter-driven vmp expression locus (Fig. 
1.4). A single vmp cassette is expressed when the entire cassette is moved 
to the expression locus. 
 The majority of spirochetes are cleared from the host through specific 
anti-Vmp IgM antibodies raised against the predominantly expressed Vmps, 
which results in a significant decrease in spirochete load (from approximately 
105-107 spirochetes/mL to < 104 spirochetes/mL). The remaining spirochetes 
consist of a small population expressing different cassettes. Since the host 
has not raised a strong antibody response to these non-dominantly 
expressed Vmps, this minority population of spirochetes can proliferate to 
high concentrations until an antibody response is mounted and the majority 
of spirochetes are once again cleared. This cycle of vmp conversion, peaking 
spirochete loads, and antibody-mediated clearing repeats a minimum of two 
times resulting in the characteristic symptoms of a relapsing fever illness.  
Mechanisms of Immune Evasion by B. miyamotoi 
 
 Given the genetic similarity of B. miyamotoi to relapsing fever 
spirochetes, it is likely B. miyamotoi utilizes some homologous mechanisms 
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to evade host immune responses. While B. miyamotoi is resistant to 
complement in vitro (171, 172), complement inactivation is not required for 
relapsing fever spirochetes to establish infection. OspE homologues have 
been identified in B. miyamotoi FR64b (isolated from the blood of A. 
argenteus) however, McDowell et al. were unable to demonstrate binding of 
factor H (115). We observed factor H binding using whole-cell B. miyamotoi 
FR64b lysates and Röttgerding et al. (173) showed B. miyamotoi HT31 
expresses a functional FH-binding protein. CbiA, which binds FH in vitro. 
While the role of FH-binding remains unknown, it appears, as is the case for 
relapsing fever spirochetes, inactivation of complement may not be required 
to resolve spirochetemia during infection with B. miyamotoi (126, 174). 
 Instead, B. miyamotoi likely utilizes a Vmp system (175, 176), which 
relies on antigenic variation of Vmp. C3H/HeN mice infected with B. 
miyamotoi LB-2001 produced anti-Vsp1 IgM and IgG antibodies that were 
effective in clearing the initial spirochetemic peak of B. miyamotoi from SCID 
mice (176). Despite this clearing, a second spirochetemic relapse occurred. 
Analyses of the secondary B. miyamotoi population revealed expression of 
vlpC2, not vsp1, as would be expected in the case of antigenic variation. 
They also noted vlpC2 was present in the initial B. miyamotoi population in a 
much lower prevalence compared to vsp1.  
Problem 
 
 B. burgdorferi s.l. has had a significant impact on human health of 
both immunocompetent and immunocompromised individuals and Lyme 
disease is expected, at a minimum, to maintain its status as a public health 
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threat. The effect B. miyamotoi has had and will have remains unknown, 
though there is a clear impact on immunocompromised individuals that is 
cause for concern. 
 Despite both B. burgdorferi s.l. and B. miyamotoi being demonstrated 
human pathogens, several essential questions remain unanswered. Both 
possess uncharacterized genes, which prevent a comprehensive 
understanding of the physiology, pathogenesis, prevention, and treatment of 
Lyme disease and HTBRF. While we have a decent understanding of the 
enzootic maintenance of B. burgdorferi s.s. in the northeastern US, we are 
still filling in large holes in the enzootic maintenance of B. burgdorferi s.l. in 
other areas of North America. There are more unknowns regarding the 
enzootic maintenance of B. miyamotoi.  
 During my graduate career, I attempted to address some basic 
questions regarding B. burgdorferi s.s. and B. miyamotoi. Specifically, 1. The 
enzootic maintenance of B. burgdorferi in North Dakota, 2. The physiological 
role of proteins in the survival and pathogenesis of B. burgdorferi, and 3. The 
enzootic maintenance of B. miyamotoi.  
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CHAPTER 2 
 
THE WESTERN PROGRESSION OF LYME DISEASE:  
INFECTIOUS AND NON-CLONAL BORRELIA BURGDORFERI  
SENSU LATO POPULATIONS IN GRAND FORKS COUNTY,  
NORTH DAKOTA 
 
Introduction 
 
 Eastern North Dakota borders some Minnesota counties (i.e., Kittson, 
Marshall, Polk, and Norman) where the risk of contracting the tick-borne 
diseases Lyme disease or human granulocytic anaplasmosis is moderate to 
high based on confirmed human cases (177, 178), the abundance of Borrelia 
burgdorferi-positive Ixodes scapularis (179), and the density of nymphal I. 
scapularis (177). Despite this close geographical proximity, there has been a 
paucity of studies on the migration of I. scapularis or B. burgdorferi into 
North Dakota (38). Eastern North Dakota is classified as a transition zone for 
Lyme disease based on studies investigating the expansion of I. scapularis 
and B. burgdorferi in the Midwest (179). However, in 2011, the North Dakota 
Department of Health reported results of a 2010 survey showing established 
I. scapularis populations in six eastern North Dakota counties, including 
Grand Forks county (180). In addition, the pathogens Anaplasma 
phagocytophilum, Babesia sp., and B. burgdorferi were detected in I. 
scapularis via PCR (180). 
 Surveillance of I. scapularis has shown an increase in its geographic 
distribution (181–183), which has been accompanied by a concomitant 
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increase in the distribution of confirmed Lyme disease cases (184). The 
primary causative agents of Lyme disease differ between the US and Europe 
with B. burgdorferi sensu stricto being the primary agent in the US and B. 
afzelli and B. garinii being the primary agents in Europe (185, 186). While it 
is generally accepted that B. burgdorferi s.l. is the sole cause of Lyme 
disease in the US, there is increasing evidence that other members of the B. 
burgdorferi sensu lato complex, a group consisting of approximately 20 
closely related species, could also cause Lyme disease in the US (4–16). For 
example, B. bissettii, has been identified in DNA isolated from human sera 
samples in California residents by sequence analysis of p66; however, it has 
not been clearly associated with Lyme disease in the US because many of the 
samples that were positive for B. bissettii were also positive for 
B. burgdorferi (187). It has been demonstrated, however, to be associated 
with Lyme disease in Europe (185, 188) and has been shown to be infectious 
and pathogenic in a mouse model (189). B. americana, found in I. pacificus 
and I. minor, is predominantly found in California and South Carolina and has 
not yet been associated with Lyme disease in humans (185), but antibodies 
to B. americana have reportedly been detected in blood from Lyme disease 
patients (190). These data underscore the need to correctly identify newly 
isolated Borrelia species in order to assess their potential contribution to 
human disease. 
 Several schemes have emerged to classify presumptive Lyme disease 
Borrelia. One is based on outer surface protein C (OspC), a protein expressed 
only during transmission from vector to host (141, 144) that is required for 
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B. burgdorferi to infect mammals (143, 146). While ospC is highly 
polymorphic, many groups or types have been described (98, 149). OspC 
types are commonly used to determine a strains ability to cause 
disseminated infections in humans (98, 191, 192). OspC groups A-U have 
been identified (98, 149) with A-O, T, and U found in North America (98, 99, 
191). Groups A, B, I, K, and N have been found most commonly associated 
with disseminated infections in humans (98, 152, 193). Groups C, D, E, F, G, 
H, and M have also been found capable of causing disseminated infection in 
humans, although the occurrence of infection with these types is much lower 
(151, 193). B. burgdorferi small mammal reservoirs have been found to 
carry specific OspC types (150). For example, it has previously been shown 
Peromyscus leucopus (white-footed mouse) tested positive for groups A, B, 
D, F, G, I, and K, while Tamias striatus (eastern chipmunk) tested positive 
for groups A, D, F, G, I, K, T, and U (150). 
 Antigenic outer surface proteins (e.g., OspC) are highly variable and 
there are indications they are subject to horizontal gene transfer (194–196), 
which make them less than ideal candidates for evaluating evolutionary 
history and geographical relationships of B. burgdorferi strains. Multilocus 
sequence typing (MLST) schemes have been developed that have proven to 
be the most reliable method for determining the history and relationship 
within many bacterial genera and species, including B. burgdorferi s.l. strains 
(197, 198). MLST is based on the analysis of housekeeping genes, which are 
under strong pressure to minimize large-scale mutation events, such as 
those events seen in outer surface proteins. The B. burgdorferi MLST scheme 
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utilizes eight housekeeping genes: clpA, clpX, nifS, pepX, pyrG, rplB, recG, 
and uvrA (198). Each gene is assigned an allele number based on the 
sequence identity to previously submitted alleles. The profile produced from 
all eight loci corresponds to a sequence type (ST), which can be used to 
compare strains to determine evolutionary history and relationships. 
 With the discovery of I. scapularis and B. burgdorferi in eastern North 
Dakota, we sought to characterize previously unidentified spirochete cultures 
obtained from five hearts of Peromyscus spp. (deer mice) and Myodes 
gapperi (Southern red-backed vole) trapped in the Turtle and Forest River 
areas of eastern North Dakota. All five small mammals harbored unique or 
non-clonal populations of spirochetes determined to be B. burgdorferi s.l. The 
presence of non-clonal populations is significant as it indicates the B. 
burgdorferi populations present in eastern North Dakota are not the result of 
a recent or single migration event. Two of the five small mammals were 
carrying at least two different OspC types. OspC typing showed the infectious 
B. burgdorferi types A, B, E, F, and I are disproportionately represented in 
our samples. However, one isolate typed to the non-infectious group L and 
one typed to none of the previously described groups. B. burgdorferi M3 
(ospC group B) was obtained from M. gapperi at Forest River and predicted 
to be a highly infectious isolate. Using this isolate, we determined B. 
burgdorferi M3 is infectious in laboratory mice via both artificial and natural 
routes of exposure, culturable from mouse tissues, and survives I. scapularis 
molting. These data confirm B. burgdorferi is present in eastern North Dakota 
and is infectious and transmissible in a laboratory model.
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Materials and Methods 
 
Animal Care and Use  
 
 Infection experiments were performed per a University of North 
Dakota Institutional Animal Care and Use (UND IACUC) approved protocol 
#1101-2 at the University of North Dakota Center for Biomedical Research. 
Four to six week-old BALB/c mice (Harlan; Madison, WI) were cared for in 
accordance with the Association for Assessment and Accreditation of 
Laboratory Animal Care guidelines (Animal Welfare Assurance A3917-01) and 
the National Research Council of the National Academics Guide for the Care 
and Use of Laboratory Animals (8th edition). Wild rodents were collected, 
euthanized, and necropsied in the field as described in the UND IACUC 
approved protocol #1304-3. All efforts were made to minimize animal 
suffering. 
Sample Collection and Culturing Spirochetes 
 
 Live trapping of rodents was conducted during June and July 2012 in 
the two largest forested areas within an otherwise agricultural landscape in 
Grand Forks County: i.e., Turtle River State Park (47.94oN, -97.50oW; ca. 
254 hectares) and Forest River Biological Station and Wildlife Management 
Area (48.17oN, -97.66oW; ca 349 hectares). Sherman live traps (H.B. 
Sherman Traps; Tallahassee, Florida) were baited with peanut butter and 
oatmeal, supplied with cotton bedding, set in the evening, and recovered in 
the morning. Captured mammals were identified as M. gapperi and 
Peromyscus spp. based on morphological characteristics. This method makes 
it difficult to identify Peromyscus species in the field; thus, Peromyscus were 
36 
identified only to the genus level. However, all of the Peromyscus in this 
study were trapped deep in deciduous forests, a preferred habitat for P. 
leucopus, while P. maniculatus prefer more open terrain and/or coniferous 
forest, strongly suggesting the captured Peromyscus were P. leucopus 
(Robert Seabloom, personal communication; (199). Peromyscus spp. and M. 
gapperi were euthanized with isoflurane, necropsied, and hearts immediately 
inoculated into modified Barbour-Stoenner-Kelly (BSK-II) medium containing 
6% rabbit serum and 50 µg/mL rifampin (200). Surgical tools were sterilized 
with 95-99% ethanol prior to each necropsy to prevent possible cross-
contamination between animals. Three days later, uncontaminated cultures 
were blind passed into modified BSK-II with 6% rabbit serum without 
rifampin, incubated for three additional days, then examined for spirochetes 
via dark field microscopy. 
Amplification and Sequencing of ospA, ospC, flaB,  
16S, 16S-ile tRNA IGS, and p66  
 
 ospA, ospC, p66, and the 16S-ile tRNA IGS were obtained using 
amplification conditions previously described (201), except the annealing 
temperature was adjusted to 48°C (see Table 2.1 for primers used). 16S and 
flaB were amplified using the following conditions: 1 cycle 94°C for 5 min, 40 
cycles of 94°C for 30 sec, 50°C for 30 sec, 68°C for 1 min, 1 cycle 72°C for 5 
min. Sequencing was performed at Davis Sequencing (Davis, California). 
Chromatograms were visually inspected then the forward (coding) and 
reverse (template) strand sequences were aligned to obtain a double-
stranded consensus sequence. 16S sequences were queried using the 
Ribosomal Database Project’s Sequence Match (Seqmatch) program (202) 
37 
Table 2. 1.  Primer sequences used in this study and the predicted 
amplicon sizes. Primers obtained from other sources are 
indicated after primer name. 
Primer name Sequence (5’-3’) Predicted 
amplicon size in 
nucleotidesa 
16S For GGT CAA GAC TGA CGC TGA GTC A 136 nt 
16S Rev GGC GGC ACA CTT AAC ACG TTA G 
flaB For GGG TCT CAA GCG TCT TGG 139 nt 
flaB Rev GAA CCG GTG CAG CCT GAG 
ospA For ATG AAA AAA TAT TTA TTG GGA ATA GG 829 nt 
ospA Rev ATT CTC CTT ATT TTA AAG CG 
ospC For (200) ATG AAA AAG AAT ACA TTA AGT GC 638 nt 
ospC Rev CTT AAT TAA GGT TTT TTT GG 
p66 For GAT TTT TCT ATA TTT GGA CAC AT 755 nt 
p66 Rev TGT AAA TCT TAT TAG TTT TTC AAG 
16S IGS For AGT GCG GCT GGA TCA CCT CC 950 nt 
ileT IGS Rev 
(200) 
GTC TGA TAA ACC TGA GGT CGG A 
nid1 For CCA GCC ACA GAA TAC CAT CC 153 nt 
nid1 Rev GGA CAT ACT CTG CTG CCA TC 
recA For GTG GAT CTA TTG TAT TAG ATG AGG CT 171 nt 
recA Rev GCC AAA GTT CTG CAA CAT TAA CAC CT 
I. scap 16S For CGG TCT GAA CTC AGA TCA AG 300 nt 
I. scap 16S Rev GGG ACA AGA AGA CCC TAT C 
MLST primers for amplification and sequencing from 
borrelia.mlst.net/misc/info.asp 
clpA For AAA GAT AGA TTT CTT CCA GAC 982 nt 
clpA Rev GAA TTT CAT CTA TTA AAA GCT TTC 
clpX For GCT GCA GAG ATG AAT GTG CC 884 nt 
clpX Rev GAT TGA TTT CAT ATA ACT CTT TTG 
nifS For ATG GAT TTC AAA CAA ATA AAA AG 1049 nt 
nifS Rev GAT ATT ATT GAA TTT CTT TTA AG 
pepX For ACA GAG ACT TAA GCT TAG CAG 811 nt 
pepX Rev GTT CCA ATG TCA ATA GTT TC 
pyrG For GAT TGC AAG TTC TGA GAA TA 801 nt 
pyrG Rec CAA ACA TTA CGA GCA AAT TC 
recG For CCC TTG TTG CCT TGC TTT C 805 nt 
recG Rev GAA AGT CCA AAA CGC TCA G 
rplB For TGG GTA TTA AGA CTT ATA AGC 760 nt 
rplB Rev GCT GTC CCC AAG GAG ACA 
uvrA For GAA ATT TTA AAG GAA ATT AAA AGT AG 911 nt 
uvrA Rev CAA GGA ACA AAA ACA TCT GG 
a Predicted amplicon size was determined using the following respective accession 
versions: B. burgdorferi B31 AE000783.1 (chromosome), AE000790.2 (lp54), 
AE000792.1 (cp26); Mouse: NC_000079.6 (nid1). 
.
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and the Nucleotide Collection (nr/nt) BLAST database 
(blast.ncbi.nlm.nih.gov) to obtain genus and species identifications. flaB, 
ospA, ospC, p66, and the IGS region nucleotide sequences were queried 
using BLAST. 
NCBI Nuccore and BLAST Database Searches 
 
 Sequences were obtained by searching the NCBI nuccore database 
(www.ncbi.nlm.nih.gov/nuccore) using the following terms: Borrelia + p66; 
Borrelia + ospC; Borrelia + “outer surface protein C;” Borrelia + ospA; 
Borrelia + “outer surface protein A;” Borrelia + “intergenic spacer region;” 
Borrelia + IGS; Borrelia + 16S + 23S + IGS; Borrelia + 16S + 23S + 
“intergenic spacer region.” A search was performed in the non-redundant 
protein sequence (nr) BLAST database using the complete B. burgdorferi B31 
protein sequences for p66 (chromosome accession: NC_001318.1), OspC 
(cp26 accession: NC_001903.1), and OspA (lp54 accession: NC_001857.2). 
Alignments and Phylogeny 
 
 Sequences for ospA, ospC, p66, and the IGS regions from eastern 
North Dakota isolates were aligned along with BLAST and NCBI database 
sequences in ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2/). The shaded 
alignment was generated using BoxShade (ExPASy, 
www.ch.embnet.org/software/BOX_form.html). Duplicate sequences 
(identified as the same species and found to be 100% identical) were 
represented in the analyses by a single sequence. Sequences obtained from 
BLAST were included in analyses if the query coverage was greater than 
90%. Obtained sequences were manually trimmed to conserved regions 
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aligning to the shortest sequence obtained for the eastern North Dakota 
isolates. Trimmed sequences meeting the above criteria were then used in 
phylogenetic analyses. For OspA and OspC, a subset of sequences from each 
clade was chosen to create representative phylogenetic trees. Final 
phylogenetic analyses for OspA, OspC, and p66 were performed using the 
PHYLIP programs SeqBoot, Proml, and Consense (Version 3.695, 
http://evolution.genetics.washington.edu/phylip/). Briefly, sequence files 
were put into SeqBoot and analyzed with1000 bootstrap replicates. The 
SeqBoot output file was analyzed in Proml using the Jones-Taylor-Thornton 
model with multiple data sets, slower analysis, a random number seed of 9, 
data sets jumbled 5 times, and an outgroup root when appropriate. The 
resulting file was input into Consense to obtain a single consensus tree using 
the majority rule (extended) consensus type and treated as rooted when 
appropriate. DNA trees were created using Dnaml in PHYLIP. Trees were 
visualized using FigTree (Version 1.4, 
http://tree.bio.edu.ac.uk/software/figtree) and labeled using Adobe 
Illustrator CS3 (San Jose, California). 
OspC Typing 
 
 To sequence ospC from mixed populations, PCR products for ospC 
from samples M6, M7, and M9 were gel purified and cloned into E. coli using 
the pCR2.1 TOPO TA Cloning Kit per the manufacturer’s instructions (Life 
Technologies; Carlsbad, California). Plasmids were purified using the QIAGEN 
Plasmid Mini Prep kit (Valencia, California) and sequenced at Davis 
Sequencing. OspC amino acid sequences for previously typed isolates  
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(98, 99) were obtained from NCBI. Nucleotide sequences from the eastern 
North Dakota isolates were translated (ExPASy; web.expasy.org/translate/) 
and aligned with the previously typed isolates in ClustalW2. A Percent 
Identity Matrix (PIM) was obtained. An OspC type group was assigned to 
each eastern North Dakota isolate if the sequence did not diverge more than 
2% from a particular group (99). 
Multilocus Sequence Typing (MLST) 
 
 MLST was performed for each eastern North Dakota sample (198). 
Primer sequences for the eight housekeeping genes used (clpA, clpX, nifS, 
pepX, pyrG, recG, rplB, and uvrA) were obtained from the Imperial College 
London’s B. burgdorferi MLST website (http://borrelia.mlst.net). For 
amplification and sequencing, the outer forward and outer reverse primers 
for each gene were used. For each gene, a 50 µL reaction was set up using 
the HotStarTaq Plus Master Mix (QIAGEN) per the manufacturer’s 
instructions. Primers were added to a final concentration of 1 µM and 1 µL of 
purified genomic DNA was added. Previously described amplification 
conditions were used (198) with the following modifications: 1. The initial 
denaturing step was decreased to 5 min per the HotStarTaq Plus Master Mix 
instructions and 2. The annealing temperature for recG was decreased to 
48°C. Sequencing was performed at Eton BioSciences, Inc (San Diego, CA). 
Chromatograms were inspected for double-peaks, which indicated a mixed 
population. Chromatograms indicating mixed populations were omitted from 
further analyses. Single locus queries were performed for each sequence to 
obtain an allele number. An allelic profile query was performed with the 
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available loci for each eastern North Dakota sample using the B. burgdorferi 
MLST website. When data for eight loci were available, the query type chosen 
was “Exact or nearest match.” When less loci were available, the query type 
chosen was n-1, where n = number of available loci. 
Infectivity of B. burgdorferi M3 
 
 Six female 4-6 week old BALB/c mice were each subcutaneously 
injected with 106 spirochetes/mL. Two weeks post-injection, infection was 
preliminarily determined by assaying pre- and post-infection sera by 
enzyme-linked immunosorbent assay (ELISA). Larval I. scapularis were 
allowed to feed on infected mice as previously described (203). Briefly, 
approximately 200-300 uninfected larval I. scapularis (Oklahoma State 
University-Stillwater) were placed on infected BALB/c mice, allowed to 
attach, and feed. Four to seven days after attachment, engorged larval I. 
scapularis dropped off, were collected, and placed in a humidified chamber 
until they molted to nymphs. Mice were euthanized twenty-four hours after 
all I. scapularis detached (i.e., day 8). One tibiotarsal joint, ear pinnae, and 
the heart were collected for qPCR analysis. The second tibiotarsal joint and 
ear pinnae were cultured in BSK-II medium with 6% rabbit serum and 50 
µg/mL rifampin, blind passed, and examined by dark field microscopy as 
described above. After molting, approximately 15 infected nymphal I. 
scapularis were placed on 6 naïve female 4-6 week old BALB/c mice. 
Engorged I. scapularis, mouse tissues, and cultures were treated as 
described above.  
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Enzyme-Linked Immunosorbent Assay (ELISA) 
 
 Anti-B. burgdorferi IgG in sera from inoculated mice was detected as 
previously described (203). Briefly, 96-well plates were coated with a 10 
µg/mL B. burgdorferi lysate in a carbonate coating buffer and incubated O/N 
at 4°C. All washes were performed with PBS-Tween. Serum samples were 
diluted 1:100 in PBS. Anti-mouse IgG was diluted 1:5000 in PBS. Each serum 
sample was analyzed in triplicate. 
DNA Extraction 
 
 DNA from bacterial cultures was extracted with a 25:24:1 phenol-
chloroform-isoamyl alcohol extraction. DNA was further purified with two 
consecutive ethanol precipitations. Total (mouse and spirochete) DNA for use 
in qPCR was extracted from tibiotarsal joints using a phenol-chloroform-
isoamyl alcohol protocol and further purified with the QIAGEN DNeasy Blood 
and Tissue Kit per manufacturer’s specifications. Total DNA from hearts and 
ear pinnae was extracted using a modified DNeasy Blood and Tissue Kit 
protocol. Briefly, minced tissues were suspended in Buffer ATL with 
proteinase K and incubated O/N at 56°C. Samples were further purified per 
manufacturer’s specifications and as previously described (203). 
Quantitative PCR (qPCR) 
 
 Primers used are listed in Table 2.1. Reactions were performed using 
Bio-Rad iQ SYBR Green Supermix (Hercules, California). Mouse DNA was 
detected using primers for nidogen (nid1) and quantified against 500, 50, 5, 
0.5, 0.05, and 0.005 ng mouse DNA standards. Amplification conditions: 
95°C for 3 min, 40 cycles of 95°C for 30, 49°C for 1 min, 1 cycle of 95°C for 
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1 min, 50°C for 1 min, 1 cycle 49°C for 1 min, 49-95°C Δ0.5°C for 10 sec 
each step. B. burgdorferi DNA was detected using primers for recA and 
quantified against six B. burgdorferi DNA standards ranging in concentration 
from 10-6 to 10-1 copy number. Amplification conditions: 95°C for 3 min, 40 
cycles of 95°C for 30 sec, 50°C for 1 min, 1 cycle of 95°C for 1 min, 50°C for 
1 min, 1 cycle 50°C for 1 min, 50-95°C Δ0.5°C for 10 sec each step. Each 
sample and a no-template control were run in triplicate. 
Detection of B. burgdorferi DNA in Nymphal I. scapularis 
 
 Total DNA was extracted from I. scapularis allowed to molt to nymphs 
after feeding as larvae using a modified QIAGEN DNeasy Blood and Tissue Kit 
protocol. Ten molted I. scapularis per mouse were homogenized in Buffer 
ATL (600 µL) with proteinase K (20 µL) and incubated overnight at 56°C. 
Buffer AL was added (200 µL); tubes were vortexed and incubated at 70°C 
for 10 min. Wheat germ transfer RNA, Type V (1 µL of 10 mg/mL; R-7876, 
Sigma-Aldrich; St. Louis, Missouri) was added and tubes vortexed. Ethanol 
(230 µL, 95%) was added, tubes were vortexed, transferred to DNeasy spin 
columns, and centrifuged for 1 min at 8000 rpm. Buffer AW1 (500 µL) was 
added and centrifuged for 1 min at 8000 rom. Buffer AW2 (500 µL) was then 
added and centrifuged at 14000 rpm for 3 min. DNA was eluted from the spin 
column with 100 µL nuclease-free water twice. PCR was performed using 
primers for I. scapularis 16S, B. burgdorferi 16S, and B. burgdorferi flaB 
(Table 2.1) with the following amplification conditions: initial denaturation at 
94°C for 3 min; 40 cycles of 94°C for 30 sec, 50°C for 30 sec, 65°C for 30 
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sec; final elongation at 65°C for 5 min. Reactions were run on a 2.5% 
NuSieve gel.  
GenBank Accession Numbers 
 
 Sequences obtained in this study have been deposited with accession 
numbers KM676013-KM676070. 
Results 
 
Sequence and Phylogeny Confirm Spirochetes are  
B. burgdorferi and Represent Non-Clonal Populations 
 
 To confirm the eastern North Dakota samples were B. burgdorferi s.l., 
we sequenced 136 and 139 nucleotides of the 16S rDNA and flaB, 
respectively. The 16S rDNA sequences were queried against the Ribosomal 
Database Project. The sequences for each of the five samples returned hits to 
various Borrelia species (data not shown). A BLAST search of the flaB 
sequences obtained from all five samples showed 100% sequence identity 
matches to B. burgdorferi (data not shown). These data confirmed the 
spirochetes were members of the B. burgdorferi s.l. group. 
 To determine whether the samples represented multiple B. burgdorferi 
populations or a single population, sequencing and phylogenetic analyses 
were performed for ospA, ospC, p66, and the 16S-ile tRNA IGS. For 
comparison, various B. burgdorferi s.l. and B. hermsii sequences were 
obtained from the NCBI and BLAST databases. A BLAST search using the 
16S-ile tRNA DNA sequence from B. burgdorferi B31 returned results for B. 
burgdorferi s.l. (data not shown). There were no differences in the sequences 
of ospA and p66 for the five samples. Protein maximum likelihood analyses of 
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OspA (Fig. 2.1) and p66 (Fig. 2.2) grouped the eastern North Dakota 
samples with B. burgdorferi s.l.  
 
 
 
Figure 2. 1.  Unrooted protein maximum likelihood analysis of OspA shows 
the eastern North Dakota isolates group with North American 
B. burgdorferi. Sequences included, approximately, residues 
41-236. Node values represent bootstrap values from 1000 
replicates. Red: eastern North Dakota isolates; purple: North 
America Lyme disease-associated Borrelia; blue: Eurasia 
Lyme disease-associated Borrelia; black: unknown species. 
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Figure 2. 2.  Rooted protein maximum likelihood analysis of p66 shows the 
eastern North Dakota isolates group with North American 
B. burgdorferi. Sequences included, approximately, residues 
364-548. Node values represent bootstrap values from 1000 
replicates. Red: eastern North Dakota isolates; purple: North 
America Lyme disease-associated Borrelia; blue: Eurasia 
Lyme disease-associated Borrelia; black: unknown species; 
pink: Relapsing fever outgroup. 
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 Unlike OspA and p66, OspC showed variation among the eastern North 
Dakota samples, sharing between 66 and 100% identity (Figs. 2.3 and 2.4). 
In two of the small mammals sampled (M7 and M9), multiple B. burgdorferi 
strains were detected. With the exception of B. burgdorferi M7 Clone 7, which 
grouped with a clade consisting of both North American and Eurasian 
Borrelia, the eastern North Dakota populations grouped most closely with B. 
burgdorferi s.l. (Fig. 2.4). B. burgdorferi M9 Clones 1 and 6 were 100% 
identical across the region used for OspC analyses, but showed variation 
outside of this region, particularly at four residues immediately downstream. 
Further sequencing would be required to determine whether Clones 1 and 6 
are indeed different strains. OspC typing revealed a diverse group of 
spirochetes (Table 2.2). Interestingly, one of the isolates identified, B. 
burgdorferi M7 Clone 8, belongs to one of the rarer groups (L) to be 
identified in reservoir animals (204). One isolate, B. burgdorferi M7 Clone 7, 
did not group with OspC groups A-U. This is not surprising given it did not 
clearly group with North American B. burgdorferi s.l. Taken together, these 
data confirm non-clonal, invasive populations of B. burgdorferi are present in 
eastern North Dakota.  
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Figure 2. 3.  Alignment of OspC suggests the eastern North Dakota 
isolates are genetically distinct strains of B. burgdorferi. 
Samples M7 and M9 contain a mixture of clones. Sequences 
included, approximately, residues 25-198. B. burgdorferi B31 
(AE000792.1), N40 (DQ437463.1), B. burgdorferi A (a non-
type strain, ABQ42987.1), B (a non-type strain, 
ABK41066.1), ZS7 (AF500204.1), and JD1 (DQ437462.1), as 
well as Vsp3, an OspC ortholog found in B. hermsii (relapsing 
fever, AAA22967.1) were included for comparisons. 
Alignment was performed in ClustalW2 and shading was 
performed using ExPASy’s BoxShade. 
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Figure 2. 4.  Rooted protein maximum likelihood analysis of OspC shows 
the eastern North Dakota isolates group with North American 
B. burgdorferi. OspC groups are indicated by a vertical black 
line and single letter code. Sequences included, 
approximately, residues 25-198. Node values represent 
bootstrap values from 1000 replicates Red: eastern North 
Dakota isolates; purple: North America Lyme disease-
associated Borrelia; blue: Eurasia Lyme disease-associated 
Borrelia; black: unknown species; pink: Relapsing fever 
outgroup. 
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Table 2. 2.  OspC group for each eastern North Dakota isolate using Wang et al. 
(99) and Seinost et al. (98) groupings. 
Eastern ND Isolate OspC group 
B. burgdorferi M9 Clones 1 and 6 A 
B. burgdorferi M3 B 
B. burgdorferi M6 E 
B. burgdorferi M4 and B. burgdorferi M9 Clone 2 F 
B. burgdorferi M7 Clone 5 I 
B. burgdorferi M7 Clone 8 L 
B. burgdorferi M7 Clone 7 None 
 
The Eastern North Dakota Populations are Most Closely Related  
to B. burgdorferi Found in the Upper Midwest 
 
 MLST analysis was performed to determine the regional source of the 
eastern North Dakota populations. Loci were omitted from further analysis if 
the chromatograms suggested a mixed population for that locus (i.e., double 
peak at a single nucleotide location) (Tables 2.3 and 2.4). Sequence for all 
eight loci could be obtained only for one sample (B. burgdorferi M9), thus 
single locus analyses were performed for the remaining samples. The 
database profiles that most closely matched the incomplete eastern North 
Dakota sample profiles were obtained (Tables 2.3 and 2.4). B. burgdorferi M3 
most closely matched ST30 strains for all loci except nifS, which was 
unavailable. The available loci information for B. burgdorferi M4 matched 
ST56 strains. B. burgdorferi M6 matched at five loci to ST31 and ST229 but 
had a different recG loci than ST31 or ST229. B. burgdorferi M7 differed at 
clpA from ST225 strains. B. burgdorferi M9 matched at all eight loci to ST56 
strains. Each database strain that was the closest match to the eastern North 
Dakota samples was initially identified in the Upper Midwest (Illinois, 
Wisconsin, Minnesota, and Manitoba, Canada) (Fig. 2.5, Table 2.4). These 
data suggest the eastern North Dakota samples are most closely related to 
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Upper Midwest strains and thus, the Upper Midwest is the most probable 
source of the eastern North Dakota samples. 
 
Table 2. 3.  Allele scores for clpA, clpX, nifS, pepX, pyrG, recG, rplB, and 
uvrA and closest matching database STs. 
Eastern ND 
Isolate 
clpA clpX nifS pepX pyrG recG rplB uvrA ST 
B. burgdorferi 
M3 
19 1 - a 1 2 1 1 10 30 
B. burgdorferi 
M4 
24 - - 18 - 19 1 - 56, 
231 
B. burgdorferi 
M6 
20 4 - 3 3 1 3 - 31, 
229 
B. burgdorferi 
M7 
18 2 - - 2 8 1 - 225 
B. burgdorferi 
M9 
24 14 4 18 11 19 1 12 56, 
231 
a Chromatogram indicated a mixed population 
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Table 2. 4. Allelic profiles and sequence types (ST) for the eastern North Dakota 
samples and the most closely matching multilocus sequence typing 
database strains. Alleles that differ from the respective eastern 
North Dakota allele are highlighted. 
Sample/Strain 
 
ST clpA clpX nifS pepX pyrG recG rplB uvrA 
B. burgdorferi 
M3  19 1 -a 1 2 1 1 10 
51405b 30 19 1 5 1 2 1 1 10 
MC132 30 19 1 5 1 2 1 1 10 
MC108 30 19 1 5 1 2 1 1 10 
          
B. burgdorferi 
M4  24 - - 18 - 19 1 - 
1469205 56 24 14 4 18 11 19 1 12 
MC73 56 24 14 4 18 11 19 1 12 
MC78 56 24 14 4 18 11 19 1 12 
Mid761 56 24 14 4 18 11 19 1 12 
MC150 231 24 14 4 18 11 90 1 12 
          
B. burgdorferi 
M6 
 
20 4 - 3 3 1 3 - 
48102 31 20 4 3 3 3 3 3 3 
50302 31 20 4 3 3 3 3 3 3 
Mid471 31 20 4 3 3 3 3 3 3 
MC101 229 20 4 3 3 3 18 3 3 
MC92 229 20 4 3 3 3 18 3 3 
          
B. burgdorferi 
M7 
 
18 2 - - 2 8 1 - 
MC110 225 8 2 5 93 2 8 1 84 
MC120 225 8 2 5 93 2 8 1 84 
BP-2 225 8 2 5 93 2 8 1 84 
          
B. burgdorferi 
M9 
 
24 14 4 18 11 19 1 12 
1469205 56 24 14 4 18 11 19 1 12 
MC73 56 24 14 4 18 11 19 1 12 
MC78 56 24 14 4 18 11 19 1 12 
Mid761 56 24 14 4 18 11 19 1 12 
MC150 231 24 14 4 18 11 90 1 12 
a Chromatogram indicated a mixed population 
b Database strain identifications 
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Figure 2. 5.  Location of database STs from Table 2.4. Strains from 
Marshfield Clinic, WI were obtained from unknown locations 
in Wisconsin. All were identified from human erythema 
migran samples. The remaining strains were reported to be 
isolated from the identified location. Pink icons are ST225, 
yellow ST31, orange ST30, green ST229 and ST231, cyan 
ST56. Numbers in parentheses indicate the number of unique 
strains comprising each ST. Forest River and Turtle River 
were sites of sample collection in this study. Satellite images 
obtained from NOAA via Google Earth. 
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Needle-Injected B. burgdorferi M3 Infects and Survives in  
BALB/c Mice and is Acquired by Larval I. scapularis During Feeding  
 
 To determine whether infectious and transmissible populations were 
present in eastern North Dakota, an infection and transmission study was 
performed using B. burgdorferi M3. M3 was the only sample obtained from 
M. gapperi, whose reservoir status is unknown. Further, the OspC data 
suggested M3 was a clonal population belonging to the infectious B group. An 
ELISA of pre- and post-infection sera from mice subcutaneously injected with 
106 B. burgdorferi M3/mL showed increased anti-Borrelia antibodies 2-weeks 
post-injection (Table 2.5). Tibiotarsal joints and ear pinnae were culture-
positive, except for one mouse where culture data were unavailable due to 
contamination. B. burgdorferi flaB was detected in molted nymphs fed on five 
of the six needle-injected mice (Table 2.5). Neither B. burgdorferi 16S nor 
flaB could be positively identified in molted nymphs fed on mouse 6. B. 
burgdorferi recA was detected in one of three hearts, six of six tibiotarsal 
joints, and three of six ear pinnae (Table 2.6). The mouse nidogen gene, 
nid1, was detected in all tissues (Table 2.6). These data demonstrate B. 
burgdorferi M3 is infectious to mice, able to disseminate to multiple tissues, 
and capable of being acquired by I. scapularis during a blood meal.  
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Table 2. 5.  Summary of ELISA and culture results from mice either needle-
injected (N) with 106 cells/mL B. burgdorferi M3 or tick-infected (T), 
as well as PCR detection of B. burgdorferi flaB from nymphs reported 
as B. burgdorferi flaB positive/nymph 16S positive. 
ELISA Culture PCR 
Needle-injected 
(N) 
Tick-infected 
(T) 
Tibiotarsal joint Ear pinnae Bb/Nymph
s N T N T 
6/6 6/6 5/6a 6/6 6/6 6/6 5b/6 
a One culture contaminated after initial inoculation 
b PCR with B. burgdorferi 16S and fla were not clearly positive or negative for one 
mouse 
 
 
Table 2. 6.  Summary of qPCR for needle-injected and tick-infected mice 
reported as B. burgdorferi recA positive/mouse nid1 positive. 
Needle-injected Tick-infected 
Heart Tibiotarsal 
joint 
Ear pinnae Heart Tibiotarsal 
joint 
Ear pinnae 
1/3a 6/6 3/6 6/6 6/6 6/6 
a Neither recA nor nid1 were detectable in three mice 
 
B. burgdorferi M3 Survives the I. scapularis Larval Molt  
and is Subsequently Transmitted to Naïve BALB/c mice  
During a Blood Meal  
 
 To determine whether B. burgdorferi M3 was transtadially maintained 
during the I. scapularis larval molt and capable of transmission to naïve 
mice, I. scapularis nymphs were fed on naïve BALB/c mice. Infection was 
confirmed by ELISA, which showed an increase in absorbance post-feeding 
(Table 2.5). Tibiotarsal joints and ear pinnae were all culture-positive. nid1 
and recA were detected in all six hearts, tibiotarsal joints, and ear pinnae. 
These data show B. burgdorferi M3 is transtadially maintained in I. scapularis 
and capable of dissemination in naïve hosts. 
57 
Discussion  
 
 Studies on the prevalence and spread of B. burgdorferi, I. scapularis, 
and Lyme disease in the Upper Midwest typically focus on Minnesota and 
Wisconsin (183, 205, 206). The vast majority of Lyme disease cases, and 
thus B. burgdorferi and I. scapularis, reported in the Upper Midwest are 
found in Minnesota and Wisconsin. However, there are numerous factors that 
demanded a detailed investigation of B. burgdorferi in eastern North Dakota 
(e.g., the close proximity to high-risk Minnesota counties with a history of 
Lyme disease, B. burgdorferi, and I. scapularis; the presence of known small 
mammal reservoirs; and recent studies (37, 180) identifying stable I. 
scapularis populations and B. burgdorferi in North Dakota further confirming 
the expansion of I. scapularis described in other US regions and Canada (41, 
179, 181, 182, 207)]).  
 The data presented here demonstrate the spirochetes isolated in 
eastern North Dakota from Peromyscus spp. and M. gapperi hearts are 
members of the B. burgdorferi s.l. complex. While OspA and p66 are identical 
among all of the eastern North Dakota populations, OspC typing shows they 
are distinctly non-clonal populations. The M9 population consisted of at least 
two OspC types, A and F; M7 consisted of at least two types, I and L (Table 
2.2, Fig. 2.4). B. burgdorferi M7 Clone 7 does not appear to belong to any of 
the previously defined OspC groups. In phylogenetic analyses, Clone 7 also 
does not appear to group clearly with either North American B. burgdorferi 
s.l. or Eurasian Lyme disease Borrelia (Fig. 2.4). A BLAST analysis with the 
sequence from Clone 7 returns results for B. burgdorferi s.l. OspC but with a 
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maximum identity score of 87% (data not shown). It is clear Clone 7 is a 
member of the B. burgdorferi s.l. complex, but its OspC type and infectivity 
remain unknown. Despite obtaining sequence data for a single clone, the M6 
population may consist of multiple OspC types due to difficulties obtaining 
ospC sequence prior to cloning ospC. Since less than five ospC clones were 
obtained and sequenced from three of the five eastern North Dakota 
samples, it is not possible to determine the proportion of OspC types in each 
sample. It is clear at least three of the most common OspC types known to 
cause disseminated infection in humans (A, B, and I) (98, 99) are present in 
eastern North Dakota (Table 2.2, Fig. 2.4). A more comprehensive survey is 
required to determine the presence and distribution of OspC types. 
 The MLST data, though limited, suggest the eastern North Dakota 
populations are derived from the Upper Midwest populations and not a recent 
transplant from another region. Specifically, the eastern North Dakota 
populations appear to be most closely related to strains found in Minnesota, 
Wisconsin, Illinois, and southeastern Manitoba on the Minnesota-Canada 
border. A number of the housekeeping genes appeared to be identical in the 
populations that the OspC data showed were mixed populations. Likewise, a 
number of housekeeping genes appeared to indicate mixed populations in a 
single sample when the OspC data suggested populations in each sample 
were clonal. This was surprising because the ospC gene is highly 
polymorphic, while the housekeeping genes are generally more conserved. 
Viewing the OspC and MLST data together suggest that in addition to small-
scale random mutation events, large-scale mutation events also occurred 
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with OspC. The sequence analyses, taken as a whole, suggest a regional 
population structure larger and more complex than was captured by the five 
samples partially characterized here.  
 The results of the infection study show B. burgdorferi M3 is infectious 
through both an artificial and natural route of infection. B. burgdorferi M3 is 
capable of disseminating from the site of inoculation to the heart, tibiotarsal 
joint, and ear pinnae indicating it is highly infectious (101). The ability to 
disseminate is not surprising since B. burgdorferi M3 belongs to the ospC 
group B, a group associated with disseminated disease in humans (98, 152, 
193).  
 In the US, Lyme disease remains a significant public health issue. 
From 2001 to 2011, the number of confirmed cases reported to the CDC 
averaged 24,000 making it the most reported tick-borne disease in the US 
(CDC). In 2013, the CDC released revised yearly estimates based on 
continuing studies including analyzing data from tests conducted by seven 
participating commercial laboratories in 2008 (78). Based on these analyses, 
the estimated number of individuals infected with B. burgdorferi in the US 
was revised to approximately 288,000 per year, about ten times more than 
the average yearly number of reported and confirmed Lyme disease cases. 
North Dakota is not the Lyme disease hotspot Minnesota is, but Lyme disease 
is poised to be a significant public health issue in North Dakota. The number 
of Lyme disease cases reported yearly in North Dakota is low (205 reported 
cases between 1996 and 2015, North Dakota Department of Health), 
compared to the number of cases reported in neighboring Minnesota (16,439 
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confirmed cases between 1996 and 2015, Minnesota Department of Health). 
However, just as the national cases are underestimated, there are a number 
of factors that make a reasonable argument for cases in North Dakota being 
underestimated: the classification of eastern North Dakota as a transition 
zone (179), the conventional opinion that B. burgdorferi and I. scapularis are 
not found in North Dakota, the evolving criteria for reporting and confirming 
Lyme disease, the increasing number of Lyme disease cases in North Dakota, 
and the rural nature of North Dakota.  
 To develop comprehensive, informed public health policies in both the 
US and Canada, it is imperative to understand whether I. scapularis, and 
subsequently B. burgdorferi, are expanding outside of the previously 
identified geographical regions. While changes in habitat, and the reasons for 
those changes, are outside the scope of this study, it is clear that B. 
burgdorferi and I. scapularis have migrated westward in the Upper Midwest. 
This information is relevant to North Dakota residents, visitors, and medical 
professionals who should be aware of the risk of contracting Lyme disease in 
eastern North Dakota. This information is also important beyond the borders 
of North Dakota as it provides additional data on the ever-evolving state of 
Lyme disease. 
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CHAPTER 3 
 
IN VITRO AND IN VIVO CHARACTERIZATION OF TWO ANKYRIN 
PROTEINS, BB0399 AND BBB28,  
IN BORRELIA BURGDORFERI 
 
Introduction 
 
 Lyme disease, an infection with Borrelia burgdorferi spread through 
the bite of an infected Ixodes scapularis, is the leading tick-borne disease in 
the US (4, 77). Each year 20,000-30,000 cases are reported to the CDC, but 
new estimates increase the suspected cases ten-fold to 240,000-444,000 per 
year (78). Despite the high incidence of Lyme disease, we still do not fully 
understand mechanisms B. burgdorferi utilize to cause disease and survive in 
reservoirs and vectors (208–210). One potential mechanism involves 
ankyrin-repeat (Ank) proteins, which have recently been identified in 
prokaryotes with several identified as virulence factors (211–251). Ank 
domains commonly facilitate protein-protein interactions in eukaryotes. In 
bacteria, three general functional classes of Ank proteins have been 
identified: 1. DNA-binding (252), 2. Oxidative stress response (248), and 3. 
Mimicking host Ank proteins (216, 238, 253, 254).  
 Based on BLAST searches and previous studies, our hypothesis was 
bb0399 belonged to the first functional class and bbb28 belonged to the 
second functional class.
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Ankyrin Proteins 
 
 The ankyrin-repeat domain (Ank) is one of the most common protein 
motifs and has been identified in the genomes of bacteria, archaea, 
eukaryotes, and viruses. The general structure of an ankyrin-repeat domain 
consists of a 33-residue repeat forming a series of alpha helices that stack 
upon each other forming a spring-like structure. A single domain can possess 
between 2 and 34 repeats, with prokaryotic Ank proteins having an average 
of four to six repeats for free-living/facultative host-associated and obligate 
intracellular bacteria, respectively (242).  
 Eukaryotic Ank proteins exclusively mediate protein-protein 
interactions (212) in diverse cellular processes, e.g. cell cycle regulation, 
with functions such as transcription factors (246), toxins (widow spider 
neurotoxins, (255)), and nucleases (RNase L, (256)). While less is known 
regarding the role of bacterial Ank proteins, a handful have been 
characterized to some degree and it is increasingly clear that Ank domains 
are important virulence factors and play important roles in the survival of 
bacteria (211, 216, 218, 238, 240, 248, 249, 252–254, 257, 258). One 
theme that has emerged is the role of Ank proteins in mediating some aspect 
of oxidative stress, with the two best characterized examples being AnkA 
from Anaplasma phagocytophilum and AnkB from Pseudomonas aeruginosa.  
AnkA  
 
 DNA-binding Ank proteins have been identified in Anaplasma (259) 
and Ehrlichia (244). One of the better characterized is AnkA, a secreted, 
soluble protein from A. phagocytophilum, a Gram-negative, obligate 
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intracellular pathogen living in neutrophils. Once inside a neutrophil, A. 
phagocytophilum secrets AnkA via a type IV secretion system. AnkA 
translocates to the host nucleus where it: 1. Binds the host phosphatase, 
SHP-1, to interfere with host cell signaling (223, 257) and 2. Directly binds 
host DNA, specifically the cytochrome b-245 beta chain gene (CYBB) 
promoter, to decrease CYBB transcription (211, 252). Cytochrome b-245 is 
part of the oxidase system in phagocytic cells and is involved in the 
formation of superoxide radicals. 
AnkB 
 
 Pseudomonas aeruginosa is a Gram-negative, opportunistic pathogen. 
AnkB is an integral cytoplasmic membrane protein, with the Ank domain on 
the periplasmic side (248). ankB is cotranscribed in a small operon with katB, 
a catalase only induced in response to H2O2 (248, 260). Deletion of ankB 
decreases transcription of katB and makes cells more sensitive to H2O2 
(248). While the mechanism or function of AnkB is unknown, two hypotheses 
were proposed (248): 1. AnkB binds to and stabilizes or anchors KatB 
allowing KatB to take an optimal conformation to bind and degrade H2O2, or 
2. AnkB provides structural support for the cytoplasmic membrane to 
mitigate an increase in turgor pressure from oxygen accumulated during the 
degradation of H2O2.  
Oxidative Stress 
 
 Oxygen is toxic, even to obligate aerobic bacteria (261). An inevitable 
byproduct of aerobic cellular metabolism, especially oxidative 
phosphorylation, is the production of reactive oxygen species (ROS), such as 
64 
superoxide (O2·–) and hydrogen peroxide (H2O2) (262). If not fully detoxified, 
superoxide or intermediates can cause irreparable damage eventually leading 
to cell death. Some microaerophilic bacteria, which require low 
concentrations of atmospheric oxygen, will use oxidative phosphorylation as 
a major or sole source of ATP production. As a result, microaerophiles can 
have a full collection of ROS-neutralizing enzymes. Helicobacter pylori and 
some Campylobacter species have a superoxide dismutase (SOD) and 
catalase (263–267); these microaerophilic species are able to fully detoxify 
ROS. B. burgdorferi has no catalase and only a single manganese-dependent 
SOD identified (22, 268). In fact, B. burgdorferi has no apparent sources of 
endogenous ROS, e.g. oxidative phosphorylation, except for a putative 
flavoenzyme (bb0812) that might be a source of endogenous superoxide 
radicals (22, 268). 
Oxidative Stress and B. burgdorferi  
 
 Whereas all other known pathogens have mechanisms to obtain iron 
from hosts (e.g. siderophores) and have myriad iron-dependent enzymes, B. 
burgdorferi has no siderophores, iron-dependent enzymes, or iron transport 
mechanisms (268). Coupled with an intracellular iron concentration of less 
than 10 atoms (269), B. burgdorferi is a pathogen that does not require iron. 
The outer membrane lipid profile of B. burgdorferi is also unique among 
pathogens. In addition to lipoproteins commonly found in the outer 
membrane of most bacteria, e.g. phosphatidylethanolamine and 
phosphatidylglycerol, B. burgdorferi also incorporates a large percentage of 
eukaryotic-derived cholesterol and cholesterol-glycolipids and thus, have 
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more polyunsaturated fatty acids (36% of the total fatty acids when grown in 
vitro) compared to other bacteria (270). Because B. burgdorferi obtains 
membrane lipids from its environment, the lipid profile can be highly variable 
and reflective of the environment (271, 272). Polyunsaturated fatty acids are 
more susceptible to lipid peroxidation, a potentially lethal reaction whereby 
ROS create lipid peroxyl radicals and can eventually decrease membrane 
fluidity. 
 This unique physiology precludes B. burgdorferi from the obvious and 
well-characterized bacterial targets of ROS. B. burgdorferi is not susceptible 
to DNA damage resulting from exposure to ROS (270). Hydroxyl radicals 
from the breakdown of H2O2 can lead to protein carbonylation. While 
carbonylation can be catalyzed by any metal, there is no evidence that 
protein carbonylation occurs in B. burgdorferi as a result of ROS. The main 
targets for ROS damage are the polyunsaturated fatty acids found in B. 
burgdorferi’s membranes (270).  
 With no apparent source of endogenous ROS, B. burgdorferi likely 
encounters ROS from exogenous sources, I. scapularis, and mammalian 
hosts. Much remains unexplained regarding dissolved oxygen concentrations 
and ROS production in I. scapularis. The dissolved oxygen content in the 
midgut and salivary glands of I. scapularis have not been determined and so 
whether or to what extent B. burgdorferi encounters ROS in I. scapularis is 
unknown (273). We do know I. scapularis releases a large number of 
proteins during feeding to minimize host immune responses (107), including 
proteins that aid B. burgdorferi in various ways, particularly with ROS. Two 
66 
salivary proteins directly inhibit neutrophils from producing ROS (274) and 
Salp25D, a salivary peroxidase directly protects B. burgdorferi from 
mammalian host oxidative damage during host-to-vector transmission (275, 
276).  
 B. burgdorferi will encounter rapidly evolving oxygen concentrations as 
it disseminates throughout a host. In rats, there is a concentration gradient 
of dissolved oxygen with a four-fold higher concentration in arterial blood 
than skin (273, 277, 278). Based on this, one hypothesis is that B. 
burgdorferi will encounter much lower concentrations of ROS in the host’s 
dermal layer until it encounters neutrophils. In addition to the neutrophil’s 
intracellular oxidative burst, which releases ROS within a phagolysosome to 
kill pathogens, neutrophils can release ROS into the extracellular space (276, 
279, 280). Oxygen and ROS concentrations will likely vary by host organ and 
the extent of oxygenation in areas where B. burgdorferi reside, e.g. 
connective tissue at the base of the heart, is unknown. Still, B. burgdorferi 
will have to survive some exposure to oxygen and ROS.  
 Studies on the effects of oxidative stress, particularly from hydrogen 
peroxide (H2O2) on B. burgdorferi have produced conflicting results with 
some groups showing B. burgdorferi is resistant to H2O2 (281) and others 
showing B. burgdorferi is susceptible (282, 283). Recently, Troxell et al. 
(282) confirmed wild-type B. burgdorferi is resistant to oxidative stress and 
demonstrated the discrepancies in previous studies may be due to the 
presence of pyruvate in B. burgdorferi culture medium. Pyruvate is a potent 
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scavenger of H2O2 and added in excess of physiological concentrations in B. 
burgdorferi culture medium.  
B. burgdorferi Ankyrin Proteins 
 
 B. burgdorferi possesses two genes encoding proteins with Ank 
domains, bb0399 and bbb28. These genes are two of the 588 hypothetical 
proteins in the B. burgdorferi genome. Both bb0399 and bbb28 are actively 
transcribed (284), however, the function(s) of bb0399 and bbb28 remain 
unknown.  
B. burgdorferi bbb28 
 
 B. burgdorferi type strain B31 possesses a gene, bbb28, with a 
putative Ank domain consisting of two Ank repeats (Fig. 3.1). bbb28 is 
located on circular plasmid 26 (cp26), a plasmid essential for B. burgdorferi 
survival (285), and is highly conserved among B. burgdorferi strains (89-
100% sequence identity). A few studies have identified bbb28 or BBB28 but 
those that have suggest bbb28 is functional, transcribed, and translated. 
Yang et al. (286) found BBB28 co-precipitated with the inner membrane 
protein, La7. Caimano et al. (287) found bbb28 decreased by approximately 
half when the response regulator, rrp1, was knocked out. Rrp1, part of the 
Hk1/Rrp1 two-component system, is vital for B. burgdorferi survival in I. 
scapularis (288–290). Ojaimi et al. (284) found bbb28 was one of 50 highly 
transcribed genes and transcription was high independent of temperature 
(35°C used to mimic a mammalian infection and 23°C used to mimic I. 
scapularis colonization) in wild-type (wt) B. burgdorferi type strain B31. 
Ojaimi et al. (291) also compared global transcription in a wild-type, virulent 
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Figure 3. 1.  Predicted features of BB0399 and BBB28 using European 
Molecular Biology Laboratory’s Simple Modular Architecture 
Research Tool database (EMBL SMART). A. BB0399 has four 
Ank repeats and four regions of low complexity (pink boxes at 
aa 14-29 and aa 202-211; two regions are not shown at aa 
106-114 and 184-197). B. BBB28 has two Ank repeats and 
two predicted transmembrane domains. (EMBL SMART found 
at http://smart.embl-heidelberg.de/)   
 
 
B. burgdorferi B31 isolate (BL206) and a high-passage, attenuated isolate 
(B356; lacks lp25, cp32-6, and cp32-8). bbb28 transcription was higher in 
the B356 isolate. RNA-seq analysis also found bbb28 was transcribed in wild-
type B. burgdorferi B31 grown under normal conditions (292). 
 Hyde et al (293) found bbb28 transcription was downregulated in a 
mutant B31 strain, JS167, that was as resistant to oxidative stress as the 
wild-type strain, MSK5 (294). This difference in phenotype between mutant 
and wild-type was attributed to the activity of a single protein, the Borrelia 
oxidative stress regulator (BosR). In wild-type B. burgdorferi, BosR activates 
genes involved in an oxidative stress response, e.g. superoxide dismutase  
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(sodA) and neutrophil activating protein A (napA; homologous with 
Escherichia coli’s Dps, an iron-dependent DNA-binding protein that functions 
to protect DNA during starvation and oxidative stress).  B. burgdorferi B31 
strain CHP100 was found to be hyper-sensitive to tert-butyl hydroperoxide 
(t-BHP, damages outer membrane). The hyper-sensitive phenotype was due 
to a single point mutation in bosR resulting in an arginine to lysine 
substitution (bosRR39K). BosRR39K does not bind the promoter of napA but 
does bind the promoter and repress sodA. Inactivation of bosRR39K by 
transposon mutagenesis resulted in strain JS167 and restoration of the wild-
type phenotype, ROS resistant. Thus, the model proposed is that BosR 
activates transcription of oxidative stress response genes, BosRR39K 
represses transcription of those genes, and inactivation of bosRR39K 
derepresses those genes. Thus, we can infer bbb28 is activated in a wild-type 
strain, repressed by BosRR39K, and derepressed by the inactivation of 
bosRR39K. 
 Finally, signature-tagged mutagenesis (STM) of B. burgdorferi was 
able to produce bbb28::kanR mutants that were used to infect mice (105). 
Culture and PCR of five tissues were utilized to screen tissues for B. 
burgdorferi at two and four weeks post-infection. The overall trend was one 
of defective dissemination and/or survival of bbb28::kanR mutants outside of 
the inoculation site.  
B. burgdorferi bb0399  
 
 Less is known about bb0399. Expression of BB0399 is different in mid-
exponential phase compared to stationary phase. A RelA/SpoT homolog 
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(RelBbu) involved in B. burgdorferi persistence in ticks upregulates bb0399 
expression during stationary phase, however, the increase in expression is 
small compared to other RelBbu-regulated genes (log2 fold change = 1.96) 
(295). Another study, also found bb0399 transcription was also different 
during stationary phase but found bb0399 was decreased in stationary phase 
(log2 fold change = -1.3) (292)Expression in wild-type B. burgdorferi B31 is 
minimal and unaffected by temperature (284). Expression of bb0399 
becomes undetectable when rrp1 is knocked out (287). Unlike with BBB28, 
there are no data suggesting bb0399 transcripts are translated. STM was 
unable to produce a bb0399::kanR mutant suggesting bb0399 is an essential 
gene (105). 
Objective 
 
 The goal of this work was to identify the function(s) of bbb28 and 
bb0399. Our initial hypothesis focused on a BBB28 belonging to the oxidative 
stress class of ankyrin proteins. Our hypothesis stated BBB28 had a direct 
role in an oxidative stress response with an additional, or perhaps related, 
role in host dissemination. Our oxidative stress hypothesis shifted to BBB28 
not having a direct role in an oxidative stress response, rather, being 
regulated by BosR in response to unknown stimuli. Our hypothesis for 
BB0399 was that BB0399 is an essential gene and may have DNA-binding 
properties, similar to AnkA of A. phagocytophilum.
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Materials and Methods 
 
Cloning 
 
 Full-length bb0399, full-length bbb28, and truncated bbb28 (nt 187-
1245, bbb28∆186 encoding protein BBB28∆62) were cloned into five vectors 
(Table 3.1). After ligating the target gene into the vector backbone, E. coli 
Top10 was transformed with each plasmid except pMAL-p5X and pMAL-c5X, 
which were transformed into NEB Express Competent E. coli (New England 
BioLabs, Inc). Cultures were grown overnight in LB with the appropriate 
antibiotic for selection. Up to 50 colonies per transformation were screened 
by PCR for the presence of the correct insert using universal T7 or M13 
primers as appropriate. Plasmid was then extracted from up to five PCR-
positive colonies using Qiagen’s Midi Plasmid Purification kit per the 
manufacturer’s instructions. Plasmids were sent for sequencing to either 
Davis Sequencing or Eton Bio. Both strands were sequenced using either 
universal T7 or M13 primers, as appropriate. Each sequence file was visually 
inspected for sequence quality. A consensus sequence was obtained by 
aligning the coding and non-coding strand files. Consensus sequence for each 
insert was aligned to the appropriate sequence from B. burgdorferi B31. A 
cloned insert had to match 100% to B. burgdorferi B31 before proceeding to 
the transformation of an expression strain.  
 To transform an expression strain of E. coli, 50 ng of purified plasmid 
was added to 50 µL of chemically competent E. coli. Five expression strains 
were used: BL21(DE3) (Novagen), Rosetta pLysS (Novagen), Tuner 
(Novagen), Tuner pLysS (Novagen), NEB Express Competent E. coli.  
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Table 3. 1.  Cloning vectors, primers, and E. coli strains used in this study. 
Restriction sites in primers, if present, are underlined. 
Gene Plasmid 
Name 
Cloning Primers E. coli 
Strain(s) Used 
Vector 
Backbone 
bb
03
99
 
pBLS2 F: 
CGTCTAAAATTAAACACTTT
ATTAAAGG 
R: 
ATATCCAAGCATCTGATGG
G 
Top10 pCR2.1 
(Thermo 
Fisher 
Scientific) 
pBLS4 F: 
CACCATGCTTTTACTRTTAT
TGCAAACAATAATG 
R: 
GGCTATTTTACTAAAATTCG 
BL21(DE3) 
Rosetta pLysS 
Tuner 
Tuner pLysS 
pET200 
(Thermo 
Fisher 
Scientific) 
pBLS10 F: PO4-
atgaaaaaagaattcattatgctttt
actgttattgcaaaca 
R (SbfI): 
GAGAGAGACCTGCAGGCTA
TTTTACTAAAATTCG 
NEB Express pMAL-c5X 
(New England 
BioLabs, Inc) 
pBLS9 F: PO4-
ATGAAAAAAGAATTCATTAT
GCTTTTACTGTTATTGCAAA
CA 
R (SbfI): 
GAGAGAGACCTGCAGGCTA
TTTTACTAAAATTCG 
NEB Express pMAL-p5X 
(New England 
BioLabs, Inc) 
pBLS15 F (BamHI): 
CTCTCTGGATCCATGAAAAA
AGAATTCATTATGCTTTTAC
TG 
R (SalI): 
CTCTCTGTCGACCTATTTTA
CTAAAATTCGAACTATTTCT
TTGTT  
Tuner 
Tuner pLysS 
pGEX-6P-1 
(GE Healthcare 
Life Sciences) 
bb
b2
8 
pBLS1 F: 
TATAATTTAAAAATAAACTTT
AAAAGGATG 
R: 
GCAATGGAATTAATCATCAA
TTAGC 
Top10 pCR2.1 
pBLS3 F: 
CACCATGAGTTATTATGTGC
TAAGCAAAATATT 
R: 
GTTAAATACCGATTAAATAT
TTATAGATTTCACTAG 
BL21(DE3) 
Rosetta pLysS 
Tuner 
Tuner pLysS 
pET200 
pBLS8 F: PO4-
ATGAGTTATTATGTGCTAAG
CAAAATATTTCTATATTCTG
GG 
NEB Express pMAL-c5X 
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R (SbfI): 
GAGAGAGACCTGCAGGTTA
AATACCGATTAAATATTT 
pBLS7 F: PO4-
ATGAGTTATTATGTGCTAAG
CAAAATATTTCTATATTCTG
GG 
R (SbfI): 
GAGAGAGACCTGCAGGTTA
AATACCGATTAAATATTT 
NEB Express pMAL-p5X 
pBLS14 F (BamHI): 
CTCTCTGGATCCatgagttatt
atgtgctaagcaaaatattt 
R (SalI): 
CTCTCTGTCGACTTAAATAC
CGATTAAATATTTATAGATT
TC 
Tuner 
Tuner pLysS 
pGEX-6P-1 
bb
b2
8∆
18
6 
pBLS6 F: 
CACCttcaccgaaaagcaattatt
agaagattttaatattttcgaa 
R: 
GTTAAATACCGATTAAATAT
TTATAGATTTCACTAG 
BL21(DE3) 
Rosetta pLysS 
Tuner 
Tuner pLysS 
pET200 
pBLS12 F: PO4-
ATGAGTTATTATGTGCTAAG
CAAAATATTTCTATATTCTG
GG 
R (SbfI): 
GAGAGAGACCTGCAGGTTA
AATACCGATTAAATATTT 
NEB Express pMAL-c5X 
pBLS11 F: PO4-
ATGAGTTATTATGTGCTAAG
CAAAATATTTCTATATTCTG
GG 
R (SbfI): 
GAGAGAGACCTGCAGGTTA
AATACCGATTAAATATTT 
NEB Express pMAL-p5X 
pBLS13 F (BamHI): 
CTCTCTGGATCCTTCACCGA
AAAGCAATTATTAGAAGAT 
R (SalI): 
CTCTCTGTCGACTTAAATAC
CGATTAAATATTTATAGATT
TC 
Tuner 
Tuner pLysS 
pGEX-6P-1 
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Expression of Recombinant BB0399 and BBB28 
 
 Several protocols were used to attempt expression of recombinant 
BB0399 and BBB28.  
 For the traditional induction, one colony was inoculated into 50 mL 
Super Broth (SB) + 100 µL 50 µg/mL kanamycin (Kan) and grown overnight 
at 37°C. Five mL of the starter culture was subcultured into 500 mL SB + 2.5 
mL Kan and grown with shaking until OD600 was 0.4-0.6. One-hundred µL 
was removed from each flask, pelleted, and stored at -20°C (pre-induction 
sample). Isopropyl ß-D-1 thiogalactopyranoside (IPTG) was added to each 
flask to a final concentration of 0.5 mM. One-hundred µL of induced culture 
was removed 1 and 4 hours post-induction. After 4 hours, the remaining 
induced culture was pelleted (6000 x g, 10 min) and stored at -20°C. 
The same protocol was used for cultures grown and induced at 30 and 20°C. 
In addition, all three protocols were attempted with 0.1 and 1 mM IPTG. 
 Two auto-induction protocols were used. The first attempt at auto-
induction was performed using the Dual Media Set (EB + OB) (Zymo 
Research) at 37, 30, and 20°C. Protocol II, which is designed for induction of 
toxic proteins and insoluble proteins, was used. For each temperature, a 
freshly streaked colony was inoculated into 5 mL EB medium and grown at 
the appropriate temperature for 8 hours (starter culture). Fifteen mL of pre-
warmed EB medium was added with 0.25 mM IPTG to the starter culture and 
incubated for 16 hours. 
 The second attempt at auto-induction was performed using Studier’s 
methods at 37, 30, and 20°C (296). Briefly, strains were cultured in ZYM-
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5052 (rich, auto-induction medium), MDA-5052 (enriched, fully defined auto-
inducing medium), and MD-5052 (minimal, auto-inducing medium) at 37 and 
20°C without or with 0.1 mM IPTG for 16 hours. 
 Drunken induction was also attempted using a protocol was obtained 
from Dr. Suba Nookala. Briefly, an overnight culture was grown with the 
appropriate antibiotic. The overnight culture was subcultured (1:100 dilution) 
into fresh LB with the appropriate antibiotic to an OD600 of 1.4-1.8. Cultures 
were chilled to 8-10°C in an ice-water bath. One mL of culture was removed, 
pelleted, resuspended in SDS-PAGE sample buffer, and stored at -20°C. IPTG 
was added to a final concentration of 100 µM and 2% (v/v) ethanol was 
added. Cultures were induced overnight at 20°C. After induction, the culture 
was pelleted and resuspended in binding buffer (5 mM imidazole, 0.5 mM 
NaCl, 20 mM Tris-HCl, pH 8), 0.1% Triton X-100, 100 µL DNase (10000 U/mL 
stock), 1 mg/mL lysozyme, 1 mM MgCl2, and 5 mM ß-mercaptoethanol. 
Samples were homogenized by pipetting for 2-3 minutes. One mL of 50X 
phenylmethane sulfonyl fluoride (PMSF) was added. The lysate was sonicated 
on ice and centrifuged at 8000 rpm, 4o°C, 30 min. Supernatants were 
removed (soluble protein fraction) and both supernatants and pellets were 
saved and analyzed by SDS-PAGE. 
 All whole cell lysates (pre- and post-induction) and purified protein 
fractions were analyzed via SDS-PAGE.  
Growth Curves 
 
 pBLS4 (bb0399 in pET200) and pBLS3 (bbb28 in pET200) in Tuner, 
Tuner pLysS, and Rosetta pLysS and pBLS9 (bb0399 in pMAL-p5X) and 
76 
pBLS7 (bbb28 in pMAL-p5X) in NEB Express were grown in LB, LB + 1% 
glucose, LB + 1% glycerol, SB, ZYM-5052, MDA-5052, MD-5052, and MDG 
(non-inducing medium) at 20 and 37°C for 140 and 68 hours, respectively, 
using a Bioscreen C Analyzer (Growth Curves USA). Plates were shaken 
continuously and OD600 was read every hour. 
Purification of Recombinant Proteins 
 
 Soluble (pET200, pGEX-6P-1 constructs), insoluble (pET200, pGEX-6P-
1 constructs), inclusion body (pGEX-6P-1 constructs), cytoplasmic (pMAL-c5X 
constructs), and periplasmic (pMAL-p5X constructs) fraction was extracted 
when appropriate per manufacturer’s instructions. 
 Briefly, soluble and insoluble fractions from pET200 constructs were 
isolated using B-PER II (Bacterial Protein Extraction Reagent; Pierce). Soluble 
protein fractions were purified with the MagneHis Protein Purification System 
(Promega) per manufacturer’s instructions. Protein fractions where 
recombinant BB0339, BBB28, or BBB28Δ62 would have been were they 
expressed in E. coli transformed with pMAL-c5X or pMAL-p5X were purified 
using the New England BioLab’s cytoplasmic or periplasmic (osmotic shock) 
isolation protocol, respectively. Inclusion bodies were purified Protein 
fractions from E. coli transformed with pGEX-6P-1 were purified by 
resuspending pellets in 1/20 volume PBS. Cells were sonicated on ice to lyse 
(8 cycles at 40% amp, 20 sec on, 30 sec off). Triton x-100 was added to a 
final concentration of 1% then incubated for 30 min at RT on an orbital 
shaker. Samples were centrifuged 5 min, 4°C, 10000 x g. Supernatant was 
removed and both supernatant and pellet were saved.  
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 Inclusion bodies were purified by one of two methods. The first 
method used the MagneHis Protein Purification System protocol per 
manufacturer’s instructions. The second method is as follows: 100 mL 
cultures were pelleted and resuspended in 4 mL 20 mM Tris-HCl, pH 8. Cell 
suspensions were sonicated on ice (4 cycles at 30% amp, 10 sec on, 20 sec 
off) and centrifuged (20 min, 4°C, 15000 x g). Pellets were resuspended in 
6 mL ice-cold purification buffer (2 M urea, 20 mM Tris-HCl, 0.5 M NaCl, 2% 
Triton X-100), sonicated, and centrifuged until the supernatant was clear. 
The pellet was resuspended in 5 mL solubilization buffer (20 mM Tris-HCl, 
0.5 M NaCl, 5 mM imidazole, 6 M guanidine-HCl, 1 mM ß-mercaptoethanol, 
pH 8) and incubated 60 min, RT, on an orbital shaker. Samples were 
centrifuged 30 min, 4°C, 15000 x g. Prior to analyzing samples by SDS-
PAGE, proteins resuspended in guanidine were precipitated and resuspended 
in urea using a modified protocol (297). Briefly, 200 µL of guanidine extract 
was added to 1 mL of RT 95% ethanol, incubated overnight at -80°C, then 
centrifuged at 14000 x g, 30 min, 4°C. Supernatant was removed and the 
pellet was resuspended in 250 µL of -20°C 70% ethanol, vortexed, and 
centrifuged 14000 x g, 10 min, RT. Supernatant and residual ethanol was 
removed and the pellet was air dried for 15 min. Pellets were resuspended in 
50-100 µL 8 M urea. Samples were then mixed with SDS-PAGE loading buffer 
and incubated at RT for 30 minutes before loading on a gel.  
Dot Blots 
 
 pGEX dot blots were performed using pBLS14 and pBLS15 in Rosetta 
pLysS, BL21, Tuner, and Tuner pLysS induced at 20 and 37°C as described 
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above for the traditional induction and Studier’s ZYM-5052 autoinduction 
medium. After induction, soluble fraction was isolated as described above for 
pGEX-6P-1 constructs. PVDF membranes were dipped in methanol until 
transparent then equilibrated in 1X TBS without Tween-20 for 10 minutes. 
Whatman filter paper was dipped in 1X TBS and placed on a clean weigh 
boat. The PVDF membrane was placed on the filter paper and quickly dotted 
with 1 and 2 µL of each supernatant. The membrane was removed from the 
filter paper and allowed to dry completely. The dried membrane was wet in 
methanol, briefly washed in 1X TBS, then blocked for 1 h at RT in 5% 
blocking buffer (1X TBS-T + 5% non-fat dried milk). The membrane was 
incubated with primary antibody (1:1000 mouse anti-GST, Pierce) for 2 h at 
RT. The membrane was washed eight times with 1X TBS-T then incubated 
with secondary antibody (1:10000 mouse anti-IgG, Pierce) for 1 h at RT. The 
membrane was immediately developed with the Pierce SuperSignal West Pico 
Chemiluminescent kit per manufacturer’s instructions.  
 Inclusion bodies were also analyzed via dot blot. The same protocol as 
described above was used with pET200 constructs, 1:2500 rabbit anti-His 
primary antibody (Thermo Fisher), and 1:10000 rabbit anti-IgG ECL 
secondary (GE Healthcare). 
Production of Polyclonal Anti-BBB28 Antibodies 
 
 Using the full-length BBB28 sequence, putative antigenic regions were 
determined using EMBOSS explorer antigenic tool and the Universidad 
Complutense Madrid antigenic peptide prediction tool (298). A 411 bp region 
of the putative exposed region was cloned into a pET200/D-TOPO vector 
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(Invitrogen) and expressed in Escherichia coli λDE3 BL21 Star (Invitrogen). 
Recombinant protein was purified using the MagneHis Protein Purification 
System (Promega) per manufacturer’s instructions and used to produce 
polyclonal anti-BBB28 antibodies from 4- to 6-week-old C3H/HeN mice.  
Purified protein was dialyzed into 1X PBS treated for animal injection. A pre-
immune cheek bleed was obtained for each mouse and analyzed via an 
ELISA using whole-cell B. burgdorferi lysates and purified BBB28 peptide. 
Purified peptide was suspended 1:1 in Alhydrogel adjuvant 2% (InvivoGen) 
per manufacturer’s instructions. Each mouse received 50 µL of the peptide 
and adjuvant mixture intraperitoneally on day 1, 14, and 28. On day 28, 
blood was collected via submandibular bleed and analyzed via ELISA to 
confirm production of antibodies against B. burgdorferi whole cell lysate. Mice 
were then sacrificed, blood was collected, and serum was separated and 
stored at -20°C.  
Oxidative Stress 
 
Determining Effects of Preparing Culture  
for Oxidative Stress Exposure 
 
 B. burgdorferi 5A18NP1, an infectious isolate of the B31 type strain 
(299), was cultured in BSK-II medium with 6% rabbit serum (complete BSK-
II) at 34°C + 5% CO2 to a cell density of 5 x 107 cells/mL. Cells were 
centrifuged, washed, and resuspended in modified BSK-II (no rabbit serum 
or sodium pyruvate) as previously described (282) with one modification. 
Resuspended cultures were incubated at 34°C + 5% CO2 for 30 minutes in 
modified BSK-II prior to ROS exposure. A 10 mL aliquot was removed 
immediately prior to transfer, immediately after transfer, after a 30-minute 
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incubation in modified BSK-II, and then 5, 10, 20, 30, and 60 minutes post-
incubation. 
 RNA was isolated using Trizol and isopropanol precipitation. cDNA was 
synthesized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen) and 
used in quantitative PCR (qPCR). Transcripts for bosR and napA were 
normalized to flaB and compared to expression at: 1. Pre-transfer 
(+pyruvate) baseline, 2. Immediately post-transfer (-pyruvate, 0 min), or 3. 
30 minutes post-transfer (-pyruvate, 30 min).  
Oxidative Stress 
 
 B. burgdorferi 5A18NP1 was cultured in BSK-II with 6% rabbit serum 
at 34°C + 5% CO2 to a density of 5 x 107 cells/mL. Cells were centrifuged, 
washed, and resuspended as described above in modified BSK-II. After a 
30 minute acclimation period, a 10 mL aliquot was removed (time 0). One 
mM H2O2 or t-BHP were added to each culture. Ten mL aliquots were 
removed 5, 10, 20, 30, and 60 minutes post-treatment. Cultures were 
maintained in an ice-water bath until centrifuged. Pellets were washed three 
times with 1X PBS and stored at -80°C until RNA extraction. 
Quantitative Real-Time PCR 
 
 RNA was isolated using Trizol and isopropanol precipitation. cDNA was 
synthesized using the SuperScript VILO cDNA Synthesis Kit (Invitrogen) and 
used in quantitative PCR (qPCR). qPCR was performed for flaB, bosR, napA, 
sodA, bb0399, and bbb28 (primers in Table 3.2) using SYBR Green Master 
Mix (Bio-Rad) and the following protocol: 1 cycle at 95°C for 3 min, 40 cycles 
at 95°C for 30 sec and 56°C for 1 min. Melt curves were 1 cycle at 95°C for 1 
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min, 1 cycle at 56°C, 10 seconds at 56-95°C with 0.5°C temperature change 
per cycle. Transcripts were normalized to flaB. 
 
Table 3. 2.  qRT-PCR primers used in this study. 
Amplicon target Primer sequence 
flaB F: GGGTCTCAAGCGTCTTGG 
R: GAACCGGTGCAGCCTGAG 
bosR F: AGCTTGGCTTCCACAATAGC 
R: TTTGTTTCCCAGTTTTCTCCA 
napA F: GAAAGCATTGTTTGCAGTCT 
R: AAAACAATCGCAATTTTCAA 
sodA F: AGAACTTTAAGGCCAGGAAA 
R: CAATACTAACCATGCCCAAC 
bb0399 F: TGCACTAAATCTTGGAGCAGAA 
R: GCTCCGCTTTCTTTTAAAAATTC 
bbb28 F: TTCCAACGGCAATCCAATA 
R: GCGCCTTTTTCGATAAGTGA 
 
 
Results and Discussion 
 
In silico Analysis of BB0399 and BBB28 
  
 BB0399 is a small protein of 219 amino acids (Fig. 3.1A, Fig. 3.2A). It 
has four predicted Ank repeats and four predicted regions of low complexity. 
The presence of low complexity regions near the C- and N-termini suggest 
BB0399 may be a promiscuous protein with numerous binding partners 
(300). BBB28 is 414 amino acids with two predicted Ank repeats (residues 
326-355 and 359-389) and two transmembrane domains residues 5-27 and 
40-62) (Fig. 3.1B, Fig. 3.2B). Interestingly, the transmembrane domains 
predicted for BBB28 in B. burgdorferi B31 are not predicted in B. bavariensis 
PBi, a related Lyme disease Borrelia. In B. bavariensis PBi, the N-terminal 
region is annotated as a low complexity region. 
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Figure 3. 2.  Hydrophobicity plots by TopPred for BB0399 and BBB28. 
A. Hydrophobicity plot for BB0399 predicts a soluble protein. 
B. Plot predicts two transmembrane domains, indicated by 
the two hydrophobic regions near the N-terminal. 
 
 
 Hydrophobicity plots (TopPred Version 1.10, (301)) suggest BB0399 is 
a soluble protein with the Ank domain (residues 73-199) representing the 
least hydrophilic region (Fig. 3.2A). TopPred also predicted two 
transmembrane domains in BBB28 (Fig. 3.2B). Again, there is a sharp 
increase in hydrophobicity within the Ank domain (residues 326-389) 
compared to the rest of the protein (excluding the transmembrane domains).  
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 Protein BLAST (Blastp, NCBI) searches of BB0399 and BBB28 from B. 
burgdorferi B31 produced no significant matches when Borrelia spp. were 
excluded, except the conserved Ank domain structure. The Ank domain 
aligned with a variety of organisms from bacteria (e.g. Wolbachia, Bacillus, 
Lentisphaerae) to insects (e.g. Culex spp., Vollenhovia spp., Athalia spp.) to 
trees and grasses (e.g. Prunus spp., Zea spp.) to mollusks (Mizuhopecten 
spp.) (Fig. 3.3, 3.4; Tables 1 and 2 in Appendix).  
 Phyre2 is a tool that predicts protein structure through alignments and 
domain homology to create 3D models (302). The most likely models for 
BB0399 and BBB28 were produced using an intensive search (Fig. 3.5). For 
BB0399, 97% of the residues were modeled at greater than 90% confidence 
and for BBB28, 71% of the residues were modeled at greater than 90% 
confidence.  
Cloning and Recombinant Protein Expression 
 
 Numerous inductions for recombinant BB0399 and BBB28 failed 
regardless of induction conditions or expression vector used. After one failed 
induction, plasmid was extracted from cultures and sequenced. These results 
revealed a stop codon resulting in premature termination of both proteins. 
Since both bb0399 and bbb28 were sequenced prior to expression and no 
stop codons were present, this suggests bb0399 and bbb28 are toxic to E. 
coli and were mutated to prevent expression. The presence of an antibiotic 
gene on each expression plasmid and culturing under selective pressure 
prevented E. coli from removing the plasmid containing bb0399 or bbb28.  
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Figure 3. 3.  Alignment for BB0399 adapted from NCBI protein BLAST 
results. 
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Figure 3. 4.  Alignment for BBB28 adapted from NCBI protein BLAST 
results. 
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Figure 3. 5.  Predicted structures of BB0399 (A) and BBB28 (B) by Phyre2. 
Each structure is colored from the N-terminal (blue) to the  
C-terminal (red). A. Ank repeats show the most secondary 
structure (green to red helix-turn-helix motifs near the  
C-terminal). B. Putative transmembrane domains are shown 
in blue at the N-terminal. Ank repeats are in light green to 
red. 
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 A handful of induction attempts produced promising SDS-PAGE, dot 
blot, and Western results but were unable to be confirmed by additional 
methods. For example, a dot blot for the glutathione S-transferase (GST) tag 
found on recombinant protein expressed from pGEX vectors and 6X-Histidine 
(His) tag found on recombinant protein expressed from pET vectors showed 
some strains produced GST or His after induction but not before induction 
(Fig. 3.6). The negative dots did have detectable protein when stained with 
either Coomassie blue or Ponceau S.  These results confirmed inducing 
expression of recombinant BB0399 or BBB28 was possible with some strains. 
An obvious drawback of dot blots is the inability to determine whether 
antibodies are detecting the purification tag alone or tagged recombinant 
protein. Western blots with the same samples were not positive, even for the 
tag alone. 
 The goal for producing recombinant protein was to produce antibodies 
against BB0399 and BBB28 for use in in vivo experiments. In a final attempt 
to obtain antibodies to BB0399 and BBB28, a non-coding, highly antigenic 
peptide was cloned into a pET200 TOPO vector (Invitrogen) (Fig. 3.7). The 
peptides chosen covered several putative antigenic regions and at least part 
of the peptide was expected to be available for antibody binding under native 
folding conditions. There was a 50% success rate as only the bbb28 peptide 
was successfully cloned and expressed. ELISA results from mice injected with 
bbb28 peptide showed antibodies were produced that recognized whole B. 
burgdorferi lysate. 
 
88 
 
 
Figure 3. 6.  Dot blot for GST (pGEX) and His (pET) in soluble and 
inclusion body fractions isolated from Tuner and Tuner pLysS 
E. coli strains. Three E. coli strains transformed with pGEX 
constructs (columns 1-3) had detectable GST in the soluble 
fraction throughout the experiment, while the other three 
strains (columns 4-6) showed detectable GST after induction. 
Detection of His was weak throughout the experiment. 
Column 1 – E. coli Tuner bb0399 in pGEX, 2 – Tuner pLysS 
bb0399, 3 – Tuner bbb28, 4 – Tuner pLysS bbb28, 5 – Tuner 
with truncated bbb28 (bbb28Δ186), 6 – Tuner pLysS 
bbb28Δ186, 7 – Tuner bb0399 in pET200, 8 – Tuner pLysS 
bb0399, 9 – Tuner bbb28, 10 – Tuner pLysS bbb28.  
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Figure 3. 7.  Predicted antigenic peptides. (A) BB0399 peptides predicted 
to antigenic are shown as horizontal grey bars at the top of 
the plot. A region covering five putative antigenic peptides, 
marked by yellow vertical lines, was cloned into a pET200 
TOPO vector. (B) BBB28 peptides predicted to be antigenic. A 
region covering seven putative antigenic peptides, marked by 
yellow vertical lines, was cloned into a pET200 TOPO vector. 
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Growth Curves 
 
 With evidence that both BB0399 and BBB28 are toxic to E. coli and 
after several failed attempts to express recombinant protein, auto-induction 
medium was used. Smaller yields of toxic proteins can be obtained under 
certain conditions, such as inducing at lower temperatures or at higher cell 
density. During auto-induction, starter cultures are grown in non-inducing 
media containing a lac repressor, such as excess glucose. Cultures are then 
subcultured into auto-inducing media, which also contains an appropriate lac 
repressor as well as an additional carbon source. As the culture expands, 
glucose depletes, cells begin using the second carbon source, such as 
lactose, lac is no longer repressed, and recombinant protein is expressed. 
Growth curves were performed to determine the best non-inducing medium, 
auto-inducing medium, as well as the optimal length for induction. 
 All strains grew faster at 37°C (Fig. 3.9) compared to 20°C (Fig. 3.8). 
MDG was found to be the best non-inducing medium. Strains grew well in all 
auto-inducing media but for induction at 20°C, 16-24 hours was not enough 
time for cultures to reach stationary phase. Cultures required at least 40 
hours to reach stationary phase at 20°C. As a result, prior cultures were 
harvested too early. Unfortunately, longer induction times in auto-inducing 
media failed. 
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Figure 3. 8.  Growth curves for E. coli transformed with one of eight 
plasmids and cultured in eight types of media at 20°C. For all 
strains, MDG medium was found to be the best non-inducing 
medium. For auto-induction, all strains grew well in all auto-
inducing media but required much longer incubations than 
recommended (30-40 hours to reach stationary phase 
compared to the 16-24 hours recommended). 
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Figure 3. 9.  Growth curves for E. coli transformed with one of eight 
plasmids and cultured in eight types of media at 37°C. For 
unknown reasons, no data points were recorded between 29 
and 44 hours resulting in missing data points. In addition, 
two strains (bb0399 and bbb28 Tuner) did not grow in LB or 
SB. These wells were likely not inoculated with the starter 
culture.  
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 Troubleshooting failed recombinant protein expression can be a 
maddening experience as there are several factors (e.g. codon optimization, 
properties of the chosen protein, vectors, expression strains, and induction 
parameters) that can affect expression.  
Codon Usage 
 
 Borrelia tends to use rare codons much more frequently. To 
circumvent this problem, use of an E. coli strain capable of overproducing 
tRNAs for these rare codons, such as a Rosetta pLysS E. coli strain is usually 
recommended for routine expression of Borrelia proteins. Codon optimization 
(replacing rare codons with common codons) is also performed and 
recommended for genes encoded with several rare codons. Codon 
optimization was not performed as neither BB0399 nor BBB28 possess a high 
percentage of rare codons compared to other B. burgdorferi proteins. 
Expressing recombinant BB0399 and BBB28 using any E. coli transformed 
with pLysS was deemed sufficient. 
Recombinant Protein Properties 
 
 Transmembrane domains can also impede recombinant protein 
expression. Two approaches are available to express recombinant integral 
proteins: 1. Clone the protein without the transmembrane domains or 2. 
Express recombinant protein in an E. coli strain designed to express 
membrane proteins, such as the OverExpress C41(DE3) or C43(DE3) E. coli 
strains (Lucigen).  
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Vector and Expression E. coli Choice  
 
 If you adore customization, cloning is for you. Every piece of a vector 
can be customized to fit your needs. The choice of purification tag can help 
increase solubility of recombinant proteins, making them easier to purify. 
There are also non-bacterial expression systems available, which could 
eliminate several problems associated with expressing bacterial proteins. 
Induction Parameters 
 
 If using an IPTG-inducible promoter, the presence of repressors in 
culture medium, temperature before and during induction, duration of 
induction, cell concentration at the time of induction, and IPTG concentration 
used can all affect expression.  
Oxidative Stress 
 
Preparing Cultures for t-BHP Exposure  
Affects Gene Transcription  
 
 Care must be taken when determining the effect of ROS on B. 
burgdorferi. In addition to the unusual physiology (e.g. little intracellular 
iron, no oxidative phosphorylation pathway), the medium used to culture B. 
burgdorferi, BSK-II, possesses several components capable of scavenging 
ROS. The one component found to be a potent scavenger of ROS is pyruvate, 
which is added in physiological excess in BSK-II (282). Initially, H2O2 or t-
BHP were added immediately after transferring B. burgdorferi to pyruvate-
free BSK-II. Results from these experiments and knowledge of bacterial 
stress responses suggested B. burgdorferi was experiencing stress unrelated 
to the presence of ROS. To test this hypothesis, expression of two control 
genes, bosR and napA, was evaluated under three culture conditions.   
101 
 Expression of bosR and napA was found to significantly increase 
immediately after transfer to pyruvate-free medium (-pyruvate, 0 min; 
Fig. 3.10). A 30-minute incubation in pyruvate-free BSK-II returned 
expression of bosR and napA to levels seen prior to resuspension (-pyruvate, 
30 min; Fig. 3.10). Based on these results, cultures were washed and 
resuspended in pyruvate-free BSK-II and incubated for 30 minutes prior to 
the addition of either H2O2 or t-BHP. 
 
 
 
Figure 3. 10.  Preparing B. burgdorferi for exposure to ROS appears to 
affect the expression of bosR. A similar trend was observed 
with napA. 
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Transcription of bbb28, but not bb0399,  
Appears to Increase in the Presence of t-BHP  
 
 To determine the expression of bb0399 and bbb28 in response to t-
BHP, B. burgdorferi was cultured in complete BSK-II, resuspended in 
pyruvate-free BSK-II, incubated for 30 minutes then treated with 0 or 1 mM 
t-BHP. Aliquots were removed immediately prior to ROS addition and then at 
5, 10, 20, 30, and 60 minutes after addition of ROS. qRT-PCR data were 
unavailable for some time points and genes. However, expression of bbb28 
was highest 5 minutes after the addition of t-BHP and a time-dependent 
decrease in transcription was observed (Fig. 3.11).  
 Whether the changes in bbb28 transcription observed after the 
addition of t-BHP are due to the presence of ROS is still unknown. 
Undoubtedly, centrifugation, resuspension, and placement into different 
medium affect gene transcription in B. burgdorferi. To better elucidate the 
effect of ROS on bbb28 transcription, a promoter fusion or reporter strain is 
required. A reporter strain would allow direct observation of promoter 
activation in response to ROS.  
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Figure 3. 11.  Transcription of bbb28 increases after exposure to 1 mM  
t-BHP. (A) Transcription of bosR, sodA, napA, bb0399, and 
bbb28 in the absence of t-BHP. Transcription of bosR and 
bb0399 increased, while bbb28 transcription decreased over 
time in the absence of t-BHP. qRT-PCR failed for sodA at 30 
and 60 minutes, napA at 10, 20, and 30 minutes, and bbb28 
at 30 minutes. (B) Transcription in the presence of 1 mM t-
BHP. A strong increase in bbb28 transcription was observed 5 
minutes after addition of 1 mM t-BHP. qRT-PCR failed for 
sodA at 5 minutes and all transcripts at 60 minutes.  
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Conclusions 
 
 This project provided ample learning opportunities to learn new 
methods and troubleshoot methods. Unfortunately, I was unable to provide 
additional information regarding the function of BB0399 or BBB28. Both 
bb0399 and bbb28 are transcribed and others have shown at least BBB28 is 
translated (286). The placement of bb0399 on the chromosome (22) as well 
as the inability to knockout bb0399 (105) strongly suggests this is an 
essential gene. Similarly, the placement of bbb28 on cp26, an essential 
plasmid for B. burgdorferi, suggests the function of BBB28 is important, 
though not essential for survival in vitro or in mice as mutants have been 
recovered (105). In addition, understanding the function of bb0399 and 
bbb28 would add to our understanding of B. burgdorferi, regardless of 
whether this information would move from the realm of basic science into 
translational research. 
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CHAPTER 4 
 
IN VITRO CHARACTERIZATION OF BORRELIA MIYAMOTOI  
AND THE EFFECT OF AGE ON BORRELIA MIYAMOTOI INFECTION 
IN WILD-TYPE C3H/HEN MICE 
 
Introduction 
 
 Borrelia miyamotoi is a relapsing fever spirochete (20, 21, 85, 86, 
175, 303–309) carried by the same Ixodes spp. that vector and carry species 
of the Borrelia burgdorferi sensu lato (s.l.) complex in North America, 
Europe, and Asia (20, 310). While first characterized in 1995 by Fukunaga et 
al (20), B. miyamotoi was likely first reported in 1987 when Lane and 
Burgdorfer (46) noted transovarial transmission of spirochetes in I. pacificus 
and attributed the spirochetes as B. burgdorferi.  
 In general, Lyme disease Borrelia are associated with hard-shell ticks 
and relapsing fever Borrelia are associated with soft-shell ticks. In addition to 
B. miyamotoi, there are currently four documented exceptions. B. recurrentis 
is a louse-borne relapsing fever spirochete presently endemic predominantly 
to sub-Saharan Africa. B. theileri is the causative agent of bovine borreliosis 
and is transmitted by Rhipicephalus microplus, a hard-shell tick that 
parasitizes livestock (17). B. lonestari and B. turcica are genetically similar to 
relapsing fever borreliae and carried by the hard-shell ticks Amblyomma 
americanum and Hyalomma aegyptium, respectively (18, 19). The status of 
B. lonestari and B. turcica as an animal or human pathogens is unknown. 
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 B. recurrentis and B. miyamotoi are the only relapsing fever Borrelia 
transmitted by a vector other than Ornithodoros that are confirmed to cause 
human disease (82, 87–93, 311). Despite the different vectors, pathology of 
B. miyamotoi disease (BMD) or hard tick-borne relapsing fever (HTBRF) 
appears to be similar to tick-borne relapsing fever (TBRF) with 
immunocompetent patients reporting mild, recurrent but self-resolving febrile 
episodes (Fig. 4.1) (87–93). Due to the generally mild nature of B. 
miyamotoi infection, much of the attention given to B. miyamotoi has been 
from researchers intrigued by this unusual pathogen. 
 There are several questions surrounding B. miyamotoi. So far, all of 
these questions stem from our current knowledge of B. burgdorferi and the 
relapsing fever Borrelia. Without an identified natural reservoir for B. 
miyamotoi, we are limited in our ability to study the physiology of B. 
miyamotoi as well as transmission and maintenance in Ixodes in the 
laboratory. An initial hurdle to studying B. miyamotoi was the inability to 
culture B. miyamotoi in vitro. Despite initial reports of growth in Barbour-
Stoenner-Kelly-II (BSK-II) medium (20, 21, 175, 200), more recent attempts 
to culture B. miyamotoi had been unsuccessful (310, 312). In 2014 and 
2015, however, a major breakthrough was made when two in vitro culture 
systems were developed (172, 313) and subsequently modified for use in our 
laboratory (314). Additionally, to study transmission and maintenance in 
Ixodes requires an adequate animal model. Immunocompromised mice are 
able to maintain an infection (176, 315). However, an immunocompetent 
mouse model would allow for more accurate investigations of the acquisition 
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of B. miyamotoi by Ixodes as well as allow further study into the 
immunological responses by hosts. 
 
 
 
 
Figure 4. 1.  Depiction of the general course of tick-borne relapsing fever. 
Approximately seven days after an infected tick bites, an 
increase is observed in the concentration of spirochetes in 
blood. Concomitant with a peak in spirochete concentration is 
the onset of the first febrile episode. As spirochetes are 
cleared from the blood, antigenic variation of variable 
membrane proteins (VMPs) allows a second population of 
spirochetes to expand. This leads to another, yet slightly less 
severe, peak in spirochetemia and febrile episode. This cycle 
of clearing and expansion occurs for an average of three to 
ten times.  
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An Overview of the Complement System  
 
 The complement system, composed of the classical, lectin, and 
alternative branches, is a crucial component of the immune system 
(Fig. 4.2). Components of complement continuously circulate in blood making 
complement one of the first lines of defense against pathogens. Complement 
initiates an immune response by: 1. Triggering phagocytosis through 
opsonization, 2. Mediating inflammation through the release of chemotactic 
peptides, and 3. Lysing cells via the membrane attack complex (MAC, also 
called the terminal complement complex or TCC) (Fig. 4.2) (316).  
 The classical pathway is generally mediated by non-specific antibodies, 
immunoglobulin G (IgG) or IgM, binding a bacterial antigen. Importantly, 
recent studies have shown Borrelia-specific IgM is produced by a subset of B 
cells during infection and play a crucial role in clearing Borrelia (125–127, 
129–131, 317–319).  The C1 complex, composed of C1q, C1r, and C1s, 
forms upon recognition of bound IgG or IgM. C1 cleaves C2 (C2a, C2b) and 
C4 (C4a, C4b). C4b covalently binds the target’s cell surface and complexes 
with C2a to form C3 convertase, which cleaves C3 into C3a and C3b. C3b 
covalently binds the target cell surface (opsonization, facilitates phagocytosis 
of foreign cells and cellular debris), while C3a remains soluble to act as a 
mediator of inflammation. C5 convertase forms when C3b binds C3 
convertase. Not surprisingly, C5 convertase cleaves C5 into C5a, a soluble 
inflammatory mediator, and C5b. C5b binds the target cell surface and C6 
forming C5b6, which binds C7 (C5b-7) then C8. The C5b-8 complex binds C9 
(C5b-9) and facilitates polymerization of several additional C9 proteins.  
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Figure 4. 2.  Activation and regulation of complement pathways relevant to 
Borrelia spp. infection. Points of complement inhibition 
utilized by Borrelia spp. are indicated by red octagons. (A) 
Classical pathway. (B) Mannose-lectin pathway. (C) 
Alternative pathway. Red arrows indicate borrelial proteins 
that interact with a host regulatory protein. 
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These polymerized C9 proteins form the transmembrane pore of the MAC 
allowing an influx of extracellular fluid and subsequent lysis of the target cell. 
 The lectin pathway is very similar to the classical pathway, differing 
only in the initiation steps. The lectin pathway is typically initiated through 
mannose-binding lectins, a group of pattern recognition receptors (PRRs) on 
host cells, binding specific sets of carbohydrates on foreign cells (pathogen-
associated molecular patterns, PAMPs). The lectin and classical pathways 
converge at the cleavage of C2 and C4 by different mechanisms. In the lectin 
pathway, C4 and C2 cleavage occurs through mannose-binding lectin-
associated serine proteases (MASPs) (316).  
 Like the classical and lectin pathways, the alternative pathway forms a 
C3 convertase, C5 convertase, and results in the formation of the MAC. 
Unlike the classical and lectin pathways, the alternative pathway may not 
require antibody-antigen or PAMP-PRR interactions for activation. Rather, this 
pathway is initiated through hydrolysis of C3 to C3(H2O), which is thought to 
occur continuously at low levels. The pathway is propagated through 
interactions with bacterial antigens or a lack of host surface markers (e.g. 
sialic acid, glycosaminoglycans, sulfated polysaccharides) (316). 
 Factor B, after binding C3(H2O), is cleaved by factor D into Ba and Bb 
resulting in C3(H2O)Bb, the fluid-phase C3 convertase (cleaves C3 to C3a 
and C3b). C3b binds the bacterial cell surface where it complexes with 
additional factor B. Factor D again cleaves factor B, which results in the 
second, predominant and cell-bound C3 convertase (C3bBb). This cell-bound 
C3 convertase is stabilized by properdin (C3bBbP). Binding of additional C3b 
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to C3 convertase results in the formation of C5 convertase (C3bBbC3b), 
which cleaves C5 and initiates the formation of the MAC as described above.   
Inhibition of the Mammalian Complement System 
by Borrelia and Ixodes 
 
 Regulation of complement is critical for the survival of host cells (320, 
321). Numerous mechanisms have evolved in hosts to prevent aberrant 
activation of complement on host cells including the use of complement 
regulatory factors and host cell surface components (e.g. sialic acid).  
Pathogens that inhibit host complement use mechanisms that are 
inextricably tied to host regulatory processes. Borrelia use several native 
proteins to inhibit complement (i.e. factor H-binding proteins or CRASPs, 
p43, BBK32, BGA66, BGA71, CD59-like protein) (322). The following sections 
focus on the complement regulators factor H (FH), factor H-like protein-1 
(FHL-1), factor I (FI), C4-binding protein (C4bp), and CD59.  
 At least for Lyme borreliae, resistance to complement varies by strain 
and species (115, 323–327). Roughly 10% of B. burgdorferi s.s. are serum-
resistant and 90% are intermediately resistant to serum; 75% of B. afzelii 
isolates are resistant, 25% are intermediate; 100% of B. garinii isolates are 
sensitive (specifically, OspA serotypes 3, 5, 6, 7); B. bavariensis (formerly B. 
garinii OspA serotype 4) is intermediately resistant. To the best of our 
knowledge, similar comparisons of multiple strains and species have not 
been published for relapsing fever Borrelia, though complement resistance is 
not universal among relapsing fever species among the strains observed. 
Resistance to complement is important for the transmission, survival, and 
dissemination of some Borrelia spp. in mammalian and rodent hosts and 
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reservoirs (328). Infectious strains of Borrelia are masters of complement 
evasion due to the native anti-complement proteins some possess and the 
ability all infectious strains possess to co-opt tick and host complement 
regulatory proteins. 
Factor H, Factor H-Like Protein 1 (FHL-1), and Factor I 
 
 FH is an ubiquitous 150-kDa soluble protein produced by diverse cell 
types throughout the human body (e.g. hepatic cells, fibroblasts, monocytes, 
endothelial cells) (329). FH consists of 20 short consensus repeats, while 
FHL-1 is a truncated variant of FH consisting of the FH N-terminal short 
consensus repeats 1 through 7. Both FH and FHL-1 are major direct 
regulators of the alternative complement pathway. In addition, FH and FHL-1 
can directly regulate the classical and lectin pathways, though the regulatory 
roles in these pathways are minor compared to other classical and lectin 
regulatory mechanisms. Regulation is achieved through the recognition of 
self and non-self molecules via domains located on the C- and N-terminals, 
respectively (330–332). The C-terminal discriminates self from non-self 
through interactions with sialic acids, glycosaminoglycans, and sulfated 
polysaccharides, which are typically found only on host cells (333–337). FH 
binds self-molecules with high affinity to prevent activation of complement. 
FH regulates the classical and lectin pathways by acting as a co-factor for FI. 
In this capacity, FH facilitates the serine protease activity of FI in cleaving 
and inactivating C3b. The alternative pathway is regulated through FH 
targeting factor Bb, which prevents the formation of fluid-phase C3 
convertase and promotes decay (“decay acceleration activity”) of C3 and C5 
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convertases (338). For comprehensive reviews of FH and FHL-1 see 
references (329, 338, 339). 
Factor H-Binding Proteins and CRASPs 
 
 Interactions with FH are the best-studied mechanism for Borrelia 
complement inactivation and complement resistance is correlated with 
binding FH (114). Borrelia spp. bind FH and/or FHL-1 through various native 
proteins collectively termed factor H-binding proteins (FHBPs) or 
Complement Regulator-Acquiring Surface Proteins (CRASPs) (115–117). 
CRASPs can be grouped by their ability to bind only FH or both FH and FHL-1 
as well as the species specificity of binding (that is, whether a FHBP can bind 
FH from only one or several host species) (115, 117): CRASP-1 (CspA) and 
CRASP-2 (CspZ) bind both FH and FHL-1, while CRASP-3 (ErpP), CRASP-4 
(ErpC), and CRASP-5 (ErpA) bind only FH. CRASPs bind soluble FH and 
maintain it in an active conformation thereby allowing FH to inhibit 
completion of the complement response (i.e. MAC formation).  
 Several relapsing fever spirochetes bind FH in vitro (115, 340–345). 
Two FHBPs, FhbA and BhCRASP-1, have been identified in B. hermsii strains 
YOR and HS1, respectively (346, 347). However, binding FH is not as 
important for relapsing fever spirochetes to establish infection as it is for 
Lyme disease Borrelia (122, 123). Further supporting the non-essential 
nature of binding FH, Woodman et al. (122) found that despite FhbA being 
surface-exposed and strongly binding FH in vitro, only 16% of B. hermsii 
recovered from the blood of infected mice had detectable levels of bound FH.  
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C4b-Binding Protein 
 
 C4b-binding protein (C4bp) has regulatory roles in all three pathways, 
though is the major regulator of the classical and lectin pathways. C4bp 
facilitates inactivation of C4b (classical, lectin) and fluid-phase C3b 
(alternative) by binding C4b, displacing C2a, and facilitating FI-mediated 
inactivation of C3 and C5 convertases (348). 
 Some Lyme and relapsing fever Borrelia spp. bind human and various 
animal C4bp (114, 342, 343, 349, 350). A comprehensive analysis identified 
outer surface proteins associated with C4bp including OspA, Vlps, Vmps, and 
several unidentified outer surface proteins (351). Other studies, however, 
have observed no binding of C4bp by Borrelia spp. (114, 344, 352). These 
contradictory data may be due to differences in experimental design 
including the use of different strains, growth medium, temperatures, growth 
phases, and the use of recombinant versus native human C4bp. A putative 
C4bp receptor, p43, has been identified in B. burgdorferi s.l. (349). The 
relapsing fever spirochetes B. recurrentis and B. duttonii produce CihC, a 
surface lipoprotein homologous in sequence and function to fibronectin-
binding proteins of other relapsing fever spirochetes, which also binds C4bp 
(342). 
FHBP, C4bp, and Borrelia Niche 
 
 Resistance to complement is positively correlated to the infectivity of 
some Borrelia strains (327). With a higher resistance to complement, the 
more likely a bacterium can survive, disseminate, and proliferate. Co-opting 
tick proteins will protect spirochetes during the initial stages of transmission 
115 
and dissemination but sustained dissemination requires Borrelia to resist 
complement via its own native mechanisms.  
 This leads to the question of how complement sensitive strains can 
cause infection. An interesting hypothesis was developed regarding 
complement resistance and spirochete niche when a relationship was noted 
between binding of the complement inhibitors, C4bp and FH (79, 349, 350). 
Neurotropic strains (e.g. B. bavariensis, B. garinii, B. turicatae, B. duttonii, 
and to a lesser extent B. hermsii) do not have to be highly resistant to 
complement in immunoprivileged sites, such as the central nervous system. 
Finding neurotropic species strongly bind C4bp and very weakly bind FH and 
FHL-1, while species that are not neurotropic bind C4bp but preferentially 
bind FH and/or FHL-1 supports this hypothesis (349). Alitalo et al. (353) did 
find B. garinii strains isolated from neuroborreliosis patients not only express 
FHBPs not expressed by strains cultured in vitro for an extended time, but 
the FHBPs also bind FH. This implies complement-resistance, though this was 
not reported and one of the isolates (LU59) was later reported to be highly 
but not completely sensitive to complement (354). It is possible strong 
binding of FH is an artifact seen in vitro, similar to that observed with 
relapsing fever spirochetes (see section: Factor H binding proteins and 
CRASPs). Thus, binding FH is not required for neurotropic strains. Perhaps 
C4bp is sufficient to prevent complement activation during migration of 
neurotropic species from the site of inoculation to immunoprivileged sites. On 
the other hand, binding FH may be important for neurotropic strains to resist 
complement during migration and the incomplete sensitivity observed by 
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Sandholm et al. (350) may be due to in vitro culturing resulting in the 
population losing its ability to bind FH. It could also be that neither C4bp nor 
FHBPs play a role in complement-sensitive borreliae disseminating and a 
novel mechanism is utilized by complement-sensitive strains.  
CD59-Like Protein 
 
 Little information is available regarding the CD59-like protein of B. 
burgdorferi. Pausa et al. (355) demonstrated an increase in serum sensitivity 
and MAC formation in a serum-resistant B. burgdorferi isolate treated with 
anti-CD59 antibodies compared to the control treated B. burgdorferi and the 
serum-sensitive B. garinii isolate. In eukaryotic cells, CD59 is a surface-
exposed membrane protein that prevents C9 polymerization and thus the 
formation of the MAC (19,20). Still, it is not clear Borrelia possesses a 
protein homologous to mammalian or rodent CD59. While human anti-CD59 
antibodies bound a surface-exposed integral membrane protein (29 kDa), 
this protein has never been identified though several known borrelial proteins 
can and have been ruled out based on molecular weight (e.g. BGA66, 
BGA71, OspA, OspB, OspC) (322). Given the demonstrated complement-
resistance conferred by this unknown borrelial protein, more attention should 
be given to identifying and clarifying the role this protein plays in 
complement resistance. 
Complement Inhibition by Ixodes  
and Ornithodoros Salivary Proteins  
 
 A large number of proteins with a vast array of functions have been 
identified in the saliva of feeding Ixodes spp. with more being identified and 
characterized (106, 107, 356–358). While the details and mechanisms for 
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some of these proteins remain to be elucidated, the beneficial nature of 
Ixodes salivary proteins to spirochete transmission and survival has been 
established (359–363, 274, 364, 365). Ixodes saliva contain adaptive and 
innate immunomodulatory and anti-complement proteins (106, 108–113). A 
recent study demonstrated changes in the salivary protein profile over the 
course of a feeding, which has implications for the efficacy of the host 
immune response at the feeding pit and for transmitting spirochetes (357). 
Currently, several members of the anti-complement family of proteins have 
been characterized from I. scapularis, I. ricinus, and I. persulcatus including 
Salp15, Salp20, Isac, Irac I, Irac II, and Ixac-B1, -2, -3, -4, -5. 
 Salp15 is able to inhibit both adaptive and innate immune responses 
(366, 367). Salp15 binds OspC, which both serum-resistant and serum-
sensitive B. burgdorferi s.l. produce, to inhibit deposition of the MAC and 
block the recognition and binding of antibodies to OspC (361, 368–370). In 
addition, Salp15 expression increases when ticks are infected with B. 
burgdorferi (361). Interestingly, mice passively immunized with anti-Salp15 
antibodies were protected from infection with B. burgdorferi (371). 
 Salp20 inhibits the alternative complement pathway through binding 
properdin, which prevents stabilization of C3 convertase and propagation of 
the alternative pathway (113, 372, 373). In addition, Salp20 enhances the 
activity of factor H to inhibit the alternative pathway (113). Incubating a 
serum-sensitive B. garinii strain with Salp20 protected the strain from 
complement activation and lysis (372). The mechanism(s) by which Salp20 
confer(s) protection to B. garinii is unknown.  
118 
 The Isac-like family of proteins includes Isac (Ixodes scapularis 
anticomplement), Irac I (I. ricinus anticomplement), Irac II, and Ixac-B1 
through -5 (I. ricinus anticomplement). Proteins in this family are similar in 
function to Salp20 (110, 112, 374). Inhibition of the alternative complement 
pathway is achieved through targeting C3 convertase via interactions with 
properdin, as Salp20 does, and by preventing factor B from binding C3b or 
displacing factor B from C3 convertase.  
 Ornithodoros salivary gland extracts also possess proteins that inhibit 
the host immune response (118). To date, however, one complement 
inhibitor has been identified and characterized from one Ornithodoros spp. O. 
moubata, found in Africa, is the vector of the relapsing fever spirochete B. 
duttonii (119). O. moubata complement inhibitor (OmCI) is a lipocalin that 
binds to and prevents cleavage of C5 (120, 121). OmCI was found to be 
effective at inhibiting C5 cleavage in different mammalian and rodent hosts 
(121). It is unknown if OmCI protects B. duttonii or if homologous proteins 
are found in other Ornithodoros spp. 
Purpose 
 
 In this study, we investigated the acquisition of B. miyamotoi by larval 
I. scapularis and found B. miyamotoi is efficiently acquired by uninfected 
larval I. scapularis and maintained through the molting process. Unlike other 
relapsing fever Borrelia (75), B. miyamotoi does not appear to be specific to 
an Ixodes spp. In addition, we found B. miyamotoi binds human factor H in 
vitro and a potential effect of mouse age on the duration of infection in 
immunocompetent C3H/HeN. 
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Methods 
 
B. miyamotoi 
 
 An original Japanese strain of B. miyamotoi, FR64b, was kindly sent 
from Dr. Robert Gilmore (Centers for Disease Control, Fort Collins, CO) 
(chromosome sequence available under NCBI Reference Sequence ID 
NZ_CP004217.2). 
Culture Conditions 
 
 B. miyamotoi FR64b and mouse blood were cultured in MKP-F medium 
at 34°C with 5% CO2 in capped Falcon tubes (8 or 16 mL), 1 mL deep-well 
96-well plates sealed with silicone mat lids, or microcentrifuge tubes (1.5 or 
2.0 mL) (314). Rifampicin (50 µg/mL) and phosphomycin (20 µg/mL) was 
added when appropriate. For growth curves, B. miyamotoi was cultured for 
four days in MKP-F medium at 34°C + 5% CO2. Cultures were then diluted 
1:100 into fresh MKP-F, incubated at 34°C + 5% CO2. Total cells (i.e. motile 
and non-motile) were counted every 24 hours using a Petroff-Hausser 
Counting Chamber (Cat # 3900; Hausser Scientific, Horsham, PA). Cultures 
were diluted in 1X PBS when appropriate to facilitate accurate cell counts. 
Serum Sensitivity 
 
 Ten mL of 107 B. miyamotoi were centrifuged at 6000 x g for 15 min 
at room-temperature. Pellets were washed once with 1X PBS, resuspended in 
10 mL filter-sterilized normal human serum (NHS), and incubated at 34°C + 
5% CO2 for 27.5 hours. To verify spirochetes were still alive after transfer to 
human serum donated by Dr. Travis Alvine, 10 µL was viewed under 
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Darkfield. After incubation, the presence of motile spirochetes was 
determined by placing 10 µL on a slide and viewing 10 fields under Darkfield. 
Factor H Binding 
 
 1 x 106 B. miyamotoi were harvested by centrifugation and 
resuspended in 100 µL veronal buffered saline supplemented with 1mM Mg2+, 
0.15mM Ca2+, and 0.1% gelatin. Normal human serum (NHS) was incubated 
with 0.34 M EDTA to inhibit complement activation. The cell suspension was 
incubated with 1.5 mL NHS for 1 hour, washed with PBSA, and then proteins 
bound to the cells were eluted with 0.1 M glycine-HCL, pH 2. Cells were 
removed by centrifugation and the supernatant was analyzed by Western 
blotting with a mouse monoclonal anti-human Factor H antibody (Quidel). 
One µg recombinant human Factor H (aa 860-1231; ~65kDa on SDS-PAGE; 
R&D Systems) was used a positive control. 
Mouse Infections  
 
 Two to four week-old Rag1-/- C57BL/6J mice and 2-4 week-old and 6-8 
week-old C3H/HeN were infected by intraperitoneal injection of 107 
spirochetes.  Blood was collected from saphenous veins every 12 hours for 
two weeks. Mice were subcutaneously injected with sterile 0.9% saline as 
necessary. The collected blood was immediately added to 90 µL 0.11 M 
sodium citrate solution, pH 7.2. Spirochetes were cultured by adding 10 µL of 
diluted blood to 1 mL prewarmed MKP-F. The remaining blood solution was 
stored at -20°C for DNA isolation. 
 Four mice of strains 129S1, C57BL/6J, C57BL/10J, NOD/ShiLtJ, SJL, 
CBA/CaJ, DBA/1J, DBA/2J, A/J, BALB/cJ, CBA Jackson, and FVB/NJ (3-4 
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weeks old) were infected subcutaneously with 107 B. miyamotoi FR64b. Blood 
was collected from saphenous veins every 24 hours for two weeks and 
cultured as described above. Four weeks after infection, mice were perfused 
with 1X PBS. Blood, ear pinnae, brain, thymus, heart, lungs, liver, pancreas, 
spleen, kidneys, bladder, and tibiotarsal joints were collected for PCR and 
culture. 
 To determine the minimum infectious dose, groups of three 4-6 week-
old C3H/H3N mice were infected subcutaneously with the following doses of 
B. miyamotoi FR64b: 101, 102, 103, 104, or 10 5 spirochetes. Blood was 
collected every 24 hours as described above. 
Ixodes scapularis Feeding 
 
 Uninfected larval I. scapularis were obtained from the Centers for 
Disease Control (Atlanta, GA). Uninfected larvae were fed to repletion on 
infected Rag1-/- C57BL/6J. Replete larvae were collected once per day. One 
to ten larvae per day were collected, placed in 70% ethanol, and stored at 
4°C for DNA isolation and PCR. The remaining larvae were stored in vented 
conical tubes in a 95-99% humidified chamber at 23°C to molt. Ten larvae 
were collected once per week throughout the molting process. One week 
after molting, three flat nymphs were collected, placed in 70% ethanol, and 
stored at 4°C for DNA isolation and PCR. 
DNA Isolation and PCR from Ixodes Larvae and Nymphs 
 
 I. scapularis DNA was isolated by modifying a previous protocol (59). 
Ticks stored in 70% ethanol were dried at room temperature overnight. Ticks 
were crushed in 600 µL of buffer ATL (Qiagen). 20 µL proteinase K (Qiagen) 
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was added. Tubes were vortexed briefly and incubated overnight at 56°C. 
Tubes were briefly vortexed and incubated at 56°C for an additional 2 hours 
then centrifuged at maximum speed for 3 minutes at room temperature. 
Supernatants were transferred to a clean microcentrifuge tube. Ethanol 
precipitations were performed using 1/10 volume 3 M sodium acetate and 
3 volumes 95% ethanol. Samples were incubated overnight at -20°C then 
centrifuged at maximum speed for 30 minutes at 4°C. Ethanol was decanted, 
and the pellet was resuspended in 1 mL nuclease-free water. If necessary, 
resuspension of the pellet and salt was facilitated by incubating the tube at 
56°C. Samples were filtered through a Microcon DNA Fast Flow Centrifugal 
Filter Unit (Millipore). The filter membrane was washed once with 500 µL 
nuclease-free water. DNA was eluted twice with 100 µL nuclease-free water. 
Purified DNA was stored at 4°C overnight for use in PCR. 
 PCR was performed with primers for TROSPA  
(F: GTTGCTGTCCATGCTG; R: AAGTGTTCGTTTCCCTTT),  
bipA (F: AAATCCAGGAAATGTTGATG; R: GCCACCAGACTTAATAGCAC), and 
oppA1 (F: ACTCAAATGAAGTAGAATTAGAAGAG; R: 
GTAAGCGTTTCTCTGTCAATAG) using Platinum PCR SuperMix High Fidelity 
(ThermoFisher). For each reaction, 200 nM of each primer and 1 µL of DNA 
was added to 45 µL of Platinum PCR SuperMix and the following PCR cycle 
was performed: 94°C for 2 min, 45 cycles of 94°C for 15 sec, 50°C for 30 
sec, 68°C for 15 sec. Ten µL of each reaction was run on a 2% TBE gel and 
stained with ethidium bromide.  
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Rosetting Erythrocytes 
 
 The ability of B. miyamotoi FR64b to rosette human erythrocytes was 
tested as previously described (375, 376). Briefly, B. miyamotoi FR64b and 
B. burgdorferi MI-16 were cultured to approximately 106 spirochetes/mL. Red 
blood cells were separated and diluted to a final concentration of 5% in RPMI. 
The remaining whole blood was diluted 1:10 in 1X PBS. Four and six mL of B. 
miyamotoi and B. burgdorferi were centrifuged and resuspended in 500 µL 
diluted whole blood or RPMI. For one protocol, 5% erythrocytes and 
resuspended Borrelia were incubated separately for 15 minutes at 37°C. 
Erythrocytes and Borrelia were mixed at a 1:1 or 2:1 ratio then placed on a 
glass slide with a coverslip and sealed with clear nail polish. Slides were then 
incubated for 15 minutes at 23°C or 37°C. Slides were viewed under 
Darkfield immediately after incubations. For a second protocol, Borrelia were 
resuspended in diluted whole blood, placed on a glass slide, covered, and 
sealed with clear nail polish. Slides were incubated for 30 minutes at 23°C 
and 37°C then viewed under Darkfield. 
Results 
 
Growth of B. miyamotoi 
 
 B. miyamotoi was grown in modified MKP-F medium to assess the 
growth rate (Fig. 4.3). Generation time at 34°C + 5% CO2 is approximately 
16 hours, slightly longer than B. burgdorferi with a generation time of 8-12 
hours. Maximum cell density peaked at approximately 5 x 107 
spirochetes/mL, again, slightly lower than B. burgdorferi, which reaches a 
maximum density of approximately 108 spirochetes/mL. Growth curves were 
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Figure 4. 3.  Growth of B. miyamotoi in modified MKP-F medium. 
Spirochetes were counted every 24 hours. Generation time is 
approximately 16 hours and peak density is approximately 
5 x 107 cells/mL. 
 
not performed at 23°C or 37°C, however, B. miyamotoi did grow at both 
temperatures.  
Minimum Infectious Dose and the Effect  
of Mouse Strain on Infection  
 
 None of the cultures from C3H/HeN mice infected with different 
concentrations of B. miyamotoi were positive. As we have successfully 
infected C3H/HeN mice with B. miyamotoi, negative cultures represent either 
mice were not sufficiently infected or there was a problem with the medium. 
One blood sample obtained at 24 hours for each of the 129S1, C57BL/6J, 
C57BL/10J, NOD/ShiLtJ, SJL, CBA/CaJ, DBA/1J, DBA/2J, A/J, BALB/cJ, CBA 
Jackson, and FVB/NJ mice was viewed via microscopy and showed viable 
spirochetes. Unfortunately, subsequent cultures were also negative.  
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B. miyamotoi Resists Human Serum  
and Binds Human Factor H 
 
 B. miyamotoi was incubated with normal human serum (NHS). 
Immediately after resuspending spirochetes in NHS, no dead spirochetes 
were observed. This was important to ensure spirochetes were not killed 
during transfer and resuspension in NHS. Spirochetes were incubated for 
27.5 hours, after which, ten random fields were observed with Darkfield 
microscopy. Motile spirochetes were observed in all fields showing B. 
miyamotoi is resistant to human serum. 
 Sequence alignments revealed a putative factor H binding protein 
homologous to factor H binding proteins of other relapsing fever spirochetes 
(B. turicatae, B. parkeri, and B. hermsii) (Fig. 4.4). B. miyamotoi was 
incubated with normal human serum to determine whether it binds human 
factor H. Proteins bound to the surface of B. miyamotoi were removed and 
analyzed via Western blot using anti-human factor H antibodies (Fig. 4.5). A 
band of approximately 65 kDa is visible in the eluate fraction, demonstrating 
human factor H was bound by B. miyamotoi.   
Infection by Needle Inoculation is Detectable 12 Hours  
Post-Infection in Rag1-/- C57BL/6J  
and Immunocompetent C3H/HeN Mice 
 
 Spirochetes were visible in wet whole blood mounts in all six mice 24 hours post-
infection (hpi) (Fig. 4.6). However, all mice were positive by culture 12 hpi (Table 4.1). 
Rag1-/- mice became persistently infected, whereas the 3-4 week-old C3H/HeN mice 
were negative by culture 96 hpi. Blood was not routinely collected from Rag1-/- mice after 
144 hpi. Even with saline injections, it became difficult to collect blood every 12 hours. 
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As a result, blood was collected from these mice at 252 and 336 hpi. The 6-8 week-old 
C3H/HeN mice were positive by culture 12 to 72 hpi. Both mice were negative by  
culture at 84 hpi but one mouse produced a positive culture 96 hpi, while the 
other mouse produced a positive culture 144 hpi.  
 
 
Figure 4. 4.  Protein alignment shows homology between a putative factor 
H binding protein in B. miyamotoi and factor H binding 
proteins from B. turicatae, B. parkeri, and B. hermsii. 
Identical residues are highlighted in bright yellow and 
denoted with an asterisk. Residues strongly sharing similar 
biochemical properties are highlighted in light yellow and 
denoted with a colon. Residues weakly sharing similar 
biochemical properties are denoted with a period. 
 
 
 
 
 
Figure 4. 5.  B. miyamotoi binds human factor H. Recombinant human 
factor H (rhFH) is approximately 65 kDa. A band of similar 
size is present in the B. miyamotoi eluate fraction. 
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Figure 4. 6.  Spirochetes were detected in whole blood mounts 24 hpi in all 
six mice. Three representative images are shown. (A) Rag1-/- 
C57BL/6J, (B) C3H/HeN, 2-4 week-old, (C) C3H/HeN, 6-8 
week-old. 
 
 
Table 4. 1.  Presence of spirochetes determined from culture and/or microscopy. 
Time (h) Rag1-/- C57BL/6J 2-4 
wo 
WT C3H/HeN 2-4 wo WT C3H/HeN 6-8 wo 
0 -a - - - - - 
12 +b + + + + + 
24 + + + + + + 
36 + + + + + + 
48 + + + + Cc + 
60 + + + + + C 
72 + C + + + + 
84 + + + + - - 
96 + + - - - + 
108 + + - - - - 
120 + + - - - - 
132 + + - C - - 
144 + + - - + - 
156 NCd NC - - - - 
168 NC NC - - - - 
180 NC NC C C - C 
192 NC NC - - - - 
204 NC NC - - - - 
216  NC NC - - - - 
228 NC NC - - - - 
240 NC NC - - - - 
252 + + - - - - 
264 NC NC - - - - 
276 NC NC - - - - 
288 NC NC - - - - 
300 NC NC - - - - 
312 NC NC - - - - 
324 NC NC - - - - 
336 + + - - - - 
a No spirochetes detected by microscopy or culture 
b Spirochetes observed by microscopy and/or culture 
c Culture contaminated 
d No blood collected 
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B. miyamotoi does not Appear to be Vector-Specific or Exclusive 
 
 To determine whether B. miyamotoi is specific to an Ixodes spp., 
North American I. scapularis larvae were fed to repletion on infected Rag1-/- 
mice infected with a Japanese strain of B. miyamotoi (FR64b). B. miyamotoi 
FR64b was isolated from Apodemus argenteus (small Japanese field mouse) 
but is vectored by I. persulcatus (20). If B. miyamotoi is exclusive to its 
respective vector, we would not expect a Japanese strain to survive in North 
American I. scapularis. DNA extracted from I. scapularis larvae was positive 
for bipA immediately after feeding and in the weeks leading up to molting 
(Fig. 4.7). A faint PCR band is present for ticks collected from mouse 2 (M2) 
on the first day replete ticks began dropping (D1) (Fig. 4.7A). Importantly, I. 
scapularis were positive for bipA after molting to nymphs meaning B. 
miyamotoi is able to establish an infection in I. scapularis and survive the 
molting process (Fig. 4.7C). This suggests B. miyamotoi is not exclusive to 
one Ixodes spp. 
Rosetting Erythrocytes 
 
 To determine whether B. miyamotoi is capable of rosetting 
erythrocytes like some relapsing fever Borrelia, B. miyamotoi was incubated 
with whole blood and purified erythrocytes. No erythrocyte rosetting was 
observed under any conditions used (Fig. 4.8). 
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Figure 4. 7.  B. miyamotoi DNA was detected in I. scapularis throughout 
and after the molting process. PCR was performed for the 
tick-specific TROSPA gene, the relapsing fever-specific bipA 
gene, and the Lyme Borrelia-specific oppA1 gene. bipA was 
detected in each tick sample except M1 week 2 and 4. oppA1 
was not detected in any tick samples analyzed showing the 
ticks and mice are not infected with B. burgdorferi. D1: Day 
1, first day replete ticks fell off each mouse; M1: mouse 1, 
M2: mouse 2; W1: week 1, one week after ticks were 
collected; B. miya: B. miyamotoi genomic DNA, B. burg: B. 
burgdorferi genomic DNA, NTC: no DNA template added. 
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Figure 4. 8.  B. miyamotoi does not appear to rosette erythrocytes.  
B. miyamotoi was incubated 1:1 with 5% purified 
erythrocytes at 23°C. Similar results were observed at 37°C, 
with whole blood, at 1:2 (B. miyamotoi:erythrocytes) ratios, 
and with B. burgdorferi. 
 
Discussion 
 
 We can develop effective treatment and prevention methods by 
understanding the mechanisms by which a pathogen causes disease. 
Modeling human infection in the laboratory is difficult. Various animals can 
model isolated aspects of disease but generally fall short of recapitulating a 
complete human disease. To gain a full understanding of a human pathogen 
requires patching together several pieces of information, such as identifying 
virulence factors. An additional method to assess a pathogen’s ability to 
establish an infection is by determining serum susceptibility; a pathogen 
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susceptible to human sera will likely not be able to establish infection in 
humans (328, 377). B. miyamotoi has previously been shown to resist 
human serum (171, 172), however, complement resistance varies by strain 
and species with B. burgdorferi s.l. species (115, 323–327). Without a 
complete history for the strain and culture of B. miyamotoi used in our lab, 
we verified serum resistance for B. miyamotoi FR64b.  
 We showed B. miyamotoi FR64b possesses a putative FHBP and is 
capable of binding human factor H in vitro (Fig. 4.4, Fig. 4.5). Whether B. 
miyamotoi binds factor H in vivo and is a biologically relevant function 
remains to be determined. Species of the B. burgdorferi s.l. complex rely 
heavily on complement inactivation to establish an infection, while relapsing 
fever Borrelia do not (122, 123). Still, several relapsing fever Borrelia 
possess FHBPs (346, 347) and bind factor H in vitro (115, 122, 340–345). 
This begs the question if binding factor H is not biologically relevant for 
relapsing fever Borrelia, why maintain FHBPs? FHBPs are located on plasmids 
in B. burgdorferi and while significant rearrangement has occurred between 
plasmids across strains, the content has remained relatively unchanged (23). 
That is, B. burgdorferi moves genes around but has not removed or added 
genes. In addition, the FHBP found in relapsing fever Borrelia, FhbA, is also 
found on a plasmid, which is also stable (123, 346, 347). Species of the B. 
burgdorferi s.l. complex maintain numerous FHBPs but only one, FhbA and 
homologs, has been identified in relapsing fever Borrelia  (123, 346). 
Perhaps, despite plasmid stability, relapsing fever Borrelia once had but has 
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since lost several FHBPs from their genomes and FhbA may be on the 
genomic chopping block. 
Mechanisms of Immune Evasion by B. miyamotoi:  
Where We Are  
 
 Given the genetic similarity of B. miyamotoi to relapsing fever 
spirochetes, it is likely B. miyamotoi utilizes some homologous mechanisms 
to evade host immune responses. While B. miyamotoi is resistant to 
complement in vitro (171, 172), complement inactivation is not required for 
relapsing fever spirochetes to establish infection. OspE homologues have 
been identified in B. miyamotoi FR64b (isolated from the blood of A. 
argenteus) however, McDowell et al. were unable to demonstrate FH-binding 
(115). This suggests, as is the case for relapsing fever spirochetes, 
inactivation of complement may not be required to resolve spirochetemia 
during infection with B. miyamotoi (126, 174).  
 Instead, it appears B. miyamotoi utilizes a Vmp system (175) and 
Wagemakers et al. (176) recently demonstrated antigenic variation of Vmps 
in B. miyamotoi. C3H/HeN mice infected with B. miyamotoi LB-2001 
produced anti-Vsp1 IgM and IgG antibodies that were effective in clearing the 
initial spirochetemic peak of B. miyamotoi from SCID mice. Despite this 
clearing, a second spirochetemic relapse occurred. Analyses of the secondary 
B. miyamotoi population revealed expression of vlpC2, not vsp1, as would be 
expected in the case of antigenic variation. They also noted vlpC2 was 
present in the initial B. miyamotoi population in a much lower prevalence 
compared to vsp1.  
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 An additional mechanism some relapsing fever Borrelia use to evade 
host immune responses is by rosetting erythrocytes or coating the outer 
membrane in erythrocytes (375, 376, 378). Infection with species capable of 
rosetting erythrocytes, B. duttonii and B. crociduriae, is generally more 
severe than infection with species unable to rosette erythrocytes (378, 379). 
In addition to shielding Borrelia from an immune response, rosetting 
erythrocytes can result in microemboli and tissue damage (379, 379). The 
apparent inability of B. miyamotoi to rosette erythrocytes may, at least in 
part, explain the decreased severity of B. miyamotoi infection in 
immunocompetent patients.  
Mechanisms of Immune Evasion by B. miyamotoi:  
Where We Need to Be 
 
 Even though B. miyamotoi is genetically similar to relapsing fever 
spirochetes, it has evolved and exists in different vectors (Ixodes not 
Ornithodoros) with different enzootic cycles and different co-pathogens 
compared to relapsing fever spirochetes. We should not assume B. 
miyamotoi utilizes the same set of mechanisms as other relapsing fever 
spirochetes. B. miyamotoi may use a combination of relapsing fever and 
Lyme Borrelia mechanisms as well as completely novel mechanisms. There 
are many open questions regarding how B. miyamotoi evades host responses 
and establishes infection. 
 The role of IgM in clearing B. miyamotoi has not been demonstrated. 
As discussed above, IgM is key in clearing relapsing fever infections. During 
B. hermsii infections, IgM targets FhbA and other surface proteins (131). IgM 
likely is important in clearing B. miyamotoi. All immunocompromised patients 
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diagnosed with a B. miyamotoi infection developed meningoencephalitis. A 
shared factor with these patients has been treatment with rituximab, a 
monoclonal anti-CD20 antibody targeting IgM-producing CD20-positive B 
cells. Depletion of B cells may explain how B. miyamotoi is able to migrate to 
the CNS and causes meningoencephalitis in patients treated with rituximab. 
The presence of unknown complement inhibitors, however, could contribute 
to the complement-resistance of B. miyamotoi and may be useful in 
establishing infection (171, 172). 
 The effects of tick saliva on B. miyamotoi survival have not yet been 
studied. However, being vectored by Ixodes, B. miyamotoi likely takes 
advantage of the protective proteins in tick saliva. In addition, understanding 
interactions between host, vector, and pathogen will aid in the development 
of Lyme and relapsing fever prevention strategies and thus requires more 
attention. 
Needle Infection 
 
 Via intraperitoneal injection, Rag1-/- C57BL/6J mice became 
persistently infected, as expected. These mice lack mature B cells, which are 
the cells responsible for mounting a response to other relapsing fever 
Borrelia and provide an alternative immunodeficient mouse model to severe 
combined immunodeficiency (SCID) mice (125–127, 129–131, 317–319). 
Also, as expected, the C3H/HeN mice became infected. Wagemakers et al 
(176) had previously infected 6-8 week-old C3H/HeN mice and shown 
spirochetes were detected at 24 hpi. They also found three of eight mice had 
a brief relapse at 6 and 7 dpi. This lead us to wonder whether the age of the 
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mouse affected the duration and/or recurrence of spirochetemia since as with 
humans, mice show deterioration of the immune system as they age (380). 
Indeed, no recurrent spirochetemia was observed in young 
immunocompetent C3H/HeN mice (Table 4.1). A brief spirochetemic event 
was observed in older immunocompetent C3H/HeN mice (Table 4.1). It is 
possible the 6-8 week-old mice did not experience a relapse and the negative 
cultures observed were due to inadequate culturing. If this is true, the older 
mice were still infected longer than the 2-4 week-old mice.  DNA isolation 
and PCR of blood during this potential clearing event would clarify these data. 
Unfortunately, DNA isolation failed.  
Limitations of Needle-Infection 
 
 There are several inherent limitations to be considered. The use of 
needle infections as this is a less desirable method to replicate tick-borne 
infections. In addition to being an artificial method to introduce Borrelia, 
spirochete physiology and adaptation to a host can be negatively impacted. 
Tick saliva is known to contain factors that help B. burgdorferi in establishing 
infections in hosts (106–113, 274, 356–365). However, needle infections, if 
successful, represent the most efficient method for introducing Borrelia to a 
host for additional experiments. In addition, injection site can affect disease 
pathology in mice when infecting with B. burgdorferi (381). For example, 
subcutaneous injections of B. burgdorferi near the hind end of a mouse 
results in more severe joint pathology. Whether the pathology of relapsing 
fever is affected by injection site is unknown. Injection site may not affect B. 
miyamotoi disease progression considering B. burgdorferi establishes 
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persistent infections in tissues while relapsing fever Borrelia are mainly 
blood-borne pathogens. Still, it is important to keep in mind that hosts will 
not be exposed to Borrelia (Lyme or relapsing fever) by an intraperitoneal 
tick bite.  
 Multiple methods should be used to confirm infection results. A 
negative culture or blood smear does not mean an infection has cleared. One 
2-4 week-old C3H/HeN mouse was negative by microscopy but positive by 
culture at 84 hpi.  
Vector Specificity 
 
 Tick-borne relapsing fever Borrelia demonstrate strong vector 
exclusivity. For example, B. hermsii cannot establish an infection in any 
Ornithodoros spp. besides O. hermsi. The reason for this specificity is 
unknown but does appear to be universal among the soft tick-borne Borrelia. 
Analyses have shown B. miyamotoi forms regional clades or group types (85, 
86, 382). The exact groupings are still in flux as more researchers obtain 
field-caught ticks and sequence B. miyamotoi. It appears a slightly different 
strain of B. miyamotoi is carried by each species of Ixodes (vector 
specificity). For example, strains of B. miyamotoi found in I. scapularis is 
slightly different than strains found in I. pacificus, I. ricinus, or I. persulcatus 
but strains found in I. scapularis are highly similar to each other. However, 
dissimilarity in sequences should not automatically translate to vector 
specificity. It can be difficult to test vector specificity in the US as it can be 
difficult to obtain either European and Asian Borrelia or Ixodes. Through 
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sheer luck, we were able to investigate vector specificity using a Japanese 
strain of B. miyamotoi and North American I. scapularis. 
 PCR demonstrated B. miyamotoi DNA was present in Ixodes 
immediately after feeding and in the weeks leading up to the molt (Fig 4.2). 
Acquisition, however, is not sufficient to determine vector specificity. The 
presence of Borrelia DNA or ability to culture Borrelia from a tick before 
molting only demonstrates the spirochete was present in the host. For 
Borrelia to establish an infection in ticks it must survive the tick molting, a 
process during which the blood meal is digested and the tick undergoes a 
traumatic restructuring process (47, 383). 
 Detecting B. miyamotoi DNA is flat nymphs confirms the Rag1-/- mice 
were infected (Fig 4.1 and 4.2). It also demonstrates B. miyamotoi is 
acquired by feeding ticks and survives the tick molting suggesting B. 
miyamotoi can establish an infection.  
Concluding Remarks 
 
 Although B. miyamotoi is similar to other relapsing fever Borrelia, it 
has evolved, adapted, and exists in dramatically different vectors with 
different enzootic cycles and different co-pathogens. In addition, infection 
with B. miyamotoi in immunocompromised patients generally results in non-
specific symptoms (e.g. headache, malaise), recurrent fever, and 
spirochetemia characteristic of relapsing fever. However, additional 
symptoms characteristic of relapsing fever have not been demonstrated, 
namely rapid symptom onset with a crisis event. This suggests B. miyamotoi 
infection is not synonymous with relapsing fever and is, rather, a relapsing 
138 
fever-like illness (90). The cause of this slightly different disease pathology is 
unknown but there is no doubt the different lifestyle of B. miyamotoi plays a 
role. Though the differences between B. miyamotoi and other relapsing fever 
spirochetes identified thus far are minor, we should exercise caution and not 
assume B. miyamotoi is like other relapsing fever Borrelia.
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